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ABSTRACT

In an effort to search for a more selective, less toxic neuronal nicotinic
acetylcholine receptor analgesic agent in comparison to epibatidine, a series of analogs
with hybrid structures of epibatidine and ABT-594 were designed and synthesized. The
1-(pyridyloxymethyl)-7-azabicyclo[2.2.1]heptane ring systems were furnished via an
intramolecular cyclization from a trans 1,4 disubstitituted amino-cyclohexane derivative.
The functionalized cyclohexane ring was formed via a [4+2] Diels-Alder cyclization
reaction between the acetamidoacrylate and Danishefsky’s diene. These 1(pyridyloxymethyl)-7-azabicyclo[2.2.1]heptane ring systems were then tested in vitro as
potential α4β2 nicotinic acetylcholine receptor ligands with high potency and selectivity.
In addition, a series of rigid acetylcholine analogs were synthesized from cocaine
to study the conformation of acetylcholine, the endogenous neurotransmitter at the
nicotinic acetylcholine receptor. A stereoselective reduction of 2-tropinone led to the
enantioselective synthesis of the desired acetoxytropane systems. These compounds
were also tested in in vivo models for binding affinity and efficacy responses.
Anabasamine, an alkaloid isolated from the Central Asian shrub, Anabasis
aphylla, was synthesized for the first time. It was targeted due to interesting preliminary
biological activity such as exhibiting anticholinesterase activity, anti-inflammatory
activity, and facilitated an increase in hepatic alcohol dehydrogenase levels. Only
preliminary studies were performed as anabasamine is limited in quantity due to its
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difficult isolation. A versatile synthetic methodology was developed for the synthesis of
anabasamine and related nicotine analogs. This new methodology employed a pyridyl
anion addition to valerolactone, for anabasamine, or butyrolactone for the nicotine
analog, to afford 5-hydroxy-1-(6-methoxy-pyridin-3-yl)-pentan-1-one or 4-hydroxy-1-(6methoxy-pyridin-3-yl)-butan-1-one, respectively. A reductive amination provided the
piperidine ring moiety and a Suzuki coupling reaction introduced the bipyridyl moiety to
anabasamine in five steps and 23% overall yield. In addition, this methodology was
applied successfully to the synthesis of nicotine and other related analogs. In particular
the synthesis of 6-methoxynicotine, a useful drug intermediate, was generated improving
the yield from 16% over five steps to 54% over three steps.

ix
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INTRODUCTION

Nicotinic Acetylcholine Receptors (nAChRs)
Though the nicotinic acetylcholine receptor (nAChR) was one of the first
receptors to be cloned, its full mechanistic function is still elusive to scientists today. Its
importance however is greatly appreciated. A progressive understanding of the active
site has led to advances in formulating treatment for a variety of devastating central
nervous system disorders. Additionally, understanding the binding mechanism of human
nicotinic agonists and antagonists will lead the way to new nAChR drug discovery.
Studying the active site of a receptor whose three-dimensional topology is
unknown requires a multifaceted approach. One method is to carefully design molecules
that incorporate the structural qualities of known biologically active compounds to
achieve increasingly greater receptor potency. Such hybrids should take into account the
assets of known drugs such as favorable distances between atoms, functional group
moieties, and structural similarities resulting in potency without toxicity. Natural
products have repeatedly lead to the development of many beneficial drugs and usually
display unprecedented potencies. Using nature’s designs in conjunction with some
pharmacologically interesting synthetic compounds can afford drugs that not only give
insight to the active site of the receptor, but also may solve some medical dilemmas.
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Nicotinic Acetylcholine Receptor Structure and Subtypes
Nicotinic acetylcholine receptors (nAChRs), named for their affinity for nicotine
(1) versus muscarine, are pentameric, transmembrane proteins that belong to a
superfamily of ligand-gated ion channel receptors.1 Other well-known members of this
family include the glycine receptor, the γ-aminobutyric acid (GABA) receptors, and the
5-hydroxytryptamine3 (serotonin) receptor.2 The approximately 300 kDa glycoprotein
complex is widely distributed throughout the body, moderating the function of the central
nervous system (CNS), peripheral nervous system (PNS), cardiovascular and immune
systems. They direct cholinergic transmission at the neuromuscular junction of striated
muscles, at the synapse of the autonomous peripheral ganglia, as well as within certain
sections of the brain.3 Individually, these functions are performed by a different nAChR
subtype, unique in its structure and composition. A subtype is classified according to the
type and arrangement of subunits it contains. Different subunit compositions result in a
variety of biophysical profiles, and likewise, pharmacological properties.4

N
H3C

N

(S)-nicotine 1

Through amino acid sequencing of the primary structure of these distinctive
subunits, nicotinic receptors have been divided into three major sub-families.5 The first
consists of neuro-muscular nicotinic receptors found in skeletal muscle and the electric
organs of certain fish. These nAChRs are heteromeric proteins that are selectively
labeled and blocked by the antagonist α-bungarotoxin present in snake venom. The
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second consists of central nervous system neuronal nAChRs that do not bind αbungarotoxin, but have high affinity for nicotine. This subtype is also a heteromeric
protein found in the brain and central nervous system. The third subfamily contains
homoligomeric neuronal nAChRs that do bind α-bungarotoxin, but do not exhibit affinity
for nicotine.6 These ganglionic receptors are considered to be the most primordial forms
of the receptors, from which all others evolved.7
The first nAChR subclass, located in the neuro-muscular junction, is primarily
associated with regulation of skeletal muscle contractions. It has been widely studied and
classified based on its abundance in the electric organ of the Torpedo ray (Torpedo
californica). 1 The meuro-muscular subtype is composed of five subunits, two identical α
subunits (α1), one β (β2), one γ, and one δ, and referred to as α1β2δγ. These subunits
are differentiated by the makeup of their primary amino acid sequence. The five subunits
are arranged around a central pore that traverses the cell membrane. This organization
creates a pore that functions as an ion channel, selectively allowing a particular cation to
traverse the cell membrane (Figure 1).5
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Figure 1: Pentameric transmembrane nAChR; ion-channel surrounded by the subunits.5

When the endogenous neurotransmitter, acetylcholine (ACh), (2) binds to the
active site of the receptor, the cation-specific channel opens, and allows for the cation to
pass through (Na+ or K+ in the peripheral subtype), depolarizing the cell and propagating
the nerve impulse. When complete, the ion pore is shut and impermeable.2 Because it is
the ligand acetylcholine (2) that activates the receptor into its open state, the nAChR is
classified as a ligand-gated ion channel receptor

+
H3C
N
H3C
CH3

O
O

acetylcholine 2
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Numerous details of the receptor class as a whole have been revealed following
the sequencing of the primary structure of each of the subunits by Shosaka Numa and his
coworkers.8, 9 The cloned cDNA sequences revealed that each subunit (α1, β1, γ, δ)
ranges in size from 40-65 kDa.8

Hydropathy plots of the primary structures reveal that

each subunit contains four hydrophobic stretches, which are thought to form four
membrane spanning segments labeled M1, M2, M3, and M4 (Figure 2). Each segment
traverses the membrane as an α-helix and it is the M2 helix of each subunit that faces the
ion channel surrounding the receptor’s central axis and constituting the wall of the ion
pore (Figure 3). An extracellular 200 amino acid sequence amino-terminal domain
precedes the M1, M2, and M3 helices, however a 109-142 amino acid loop connects the
M3 and M4 helix. The M1-M4 domains are truncated by an extracellular C-terminus
sequence.5

Figure 2: Trans-membrane M1-M4 helices
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Figure 3: M2 helices surrounding the ion channel of the receptor

M4
M3
M1

M1
M3

M2

M4
M2

M2

M3

CENTRAL
ION PORE

M2

M1
M4

M3

M2
M1

M4
M1

M3
M4

The neuronal nicotinic acetylcholine receptor, the second subclass, is believed to
have homologous construction to the muscular subtype. However much of its structure
and function has not been well characterized due to the wide diversity of the genes
encoding for the subunits.6 Regardless, the information obtained from the muscular
subtype has allowed scientists insight into other members of the nAChR family where no
atomically resolved structure has been completed. The three-dimensional map of the
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neuronal nicotinic acetylcholine is ever evolving from a series of studies including
chemical labeling, mutagenisis experiments, electronmicroscope imaging, and patchclamp investigations.5
The neuronal nicotinic acetylcholine receptor was first introduced in 1889 by J. H.
Langley and W. L. Dickinson when they discovered that nicotine could block neuronal
transmission in the superior cervical ganglion.10 This physiological discovery led to the
concept of the presence of nicotinic receptors.11, 12 More recently, characteristics of the
neuronal structure have emerged from a combination of muscular subtype data and
advanced investigations into this biologically significant protein.
The central nervous system neuronal nicotinic acetylcholine receptor is, like the
muscular subtype, a pentameric arrangement of proteins arranged around a central pore,
creating an ion channel specific for Ca+. This protein consists of 2α subunits and 3β
subunits. The α subunits are identified by a characteristic disulfide bond between
adjacent cysteine (Cys) residues and eight α-subunits (α2-α9) have been identified in
neuronal subtypes. Neuronal β-subunits, sometimes referred to as “non-α” subunits, do
not contain the Cys-Cys moiety and are subdivided into β2, β3, and β4.13 The α4β2
combination (2α4:3β2) is the heteromeric neuronal subtype that does not bind αbungarotoxin and the most prominent subtype dispersed throughout the central nervous
system, especially in the mammalian brain.14 The active site for ligand binding is
considered to be primarily within the α subunit, but distinctly at the interface of the α and
β subunits.6 These sites are believed to be responsible for binding nicotine.
A homomeric pentamer of α7 subunits is also prevalent in the central nervous
system, but is found in the peripheral nervous system (PNS) as well.15 Its distribution in
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the brain is comparable to the α4β2 subtype, but its function is yet to be fully determined.
This subtype is thought to play a role in learning, memory, and other cognitive
functioning as well as neuroprotection.6 Because it consisted solely of α subunits, it is
predicted to have five high affinity binding sites for ligands such as α-bungarotoxin, but
not nicotine.16
Heteromeric combinations of α3, α7, β2, β3, and β4 and homomeric α9 and α7
subunits constitute the final subtype, ganglionic neuronal nicotinic acetylcholine
receptors, that has a binding affinity for α-bungarotoxin.17 This subtype is responsible
for synaptic transmission in the autonomic nervous system, adrenal catecholamine
release, and various cellular functions.6
Table 1 summarizes the various nicotinic acetylcholine receptor subtypes
discussed, their subunit makeup and location, and perceived primary function. This is
only a partial list of the subtypes found in mammals, but describes the subtypes that are
most relevant to our research.
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Table 1: Nicotinic Acetylcholine Receptor Subtypes
Classification

Subunits

Location

Neuronal (CNS)

α4β2

CNS

α7

CNS

Neuronal (Ganglionic)

α7

PNS

Muscular

α1β1δγ

Neuromuscular
Junction

Proposed Function
Memory and learning,
neurotransmitter release, pain
propagation, role in addiction
Cognitive functions,
neuroprotection
Cellular functions and
regulation
Skeletal muscle contractions

α4β2 Function in the Mammalian Brain
Though the full function of the α4β2 subunit is unknown, activation of these
nAChRs produces a variety of behavioral and physiological effects in experimental
animals and humans, including effects on cognitive performance, locomotor activity,
body temperature, respiration, cardiovascular function, and pain perception.18 Neuronal
nAChRs, which play a role in neurotransmitter release, interact with nicotine resulting in
a stimulation of acetylcholine, dopamine, norepinephrine, serotonin, GABA, and
glutamate. These neurotransmitters have been linked to the mediation and modulation of
a multitude of behaviors and disorders.13
Acetylcholine and nicotine bind with high affinity to the α4β2 subunit which is
the most prominent subtype in the mammalian brain, although precise distribution is
species dependent.6 The role of the α4β2 subtype in nicotine binding was supported by
the finding that mice with knockout genes for β2, the most widely expressed subunit in
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the central nervous system, lost their high affinity binding site for nicotine.19 The role of
this subtype has been explored in various central nervous system diseases as well as the
possibility for nicotine therapy.
Nicotine has been looked at for its ability to increase cognitive function, as it is
known to increase attention and alertness in its users. This is attributed to its ability to
increase certain catecholamine release (dopamine and norepinephrine) which are believed
to be involved in learning and memory.20 Nicotine has since been used to increase the
cognitive ability in patients with Alzheimer’s Disease, where dysfunction is associated at
the catecholaminergic systems.21 Alzheimer’s Disease is the most common form of
dementia, and as of yet there are no definite treatments or prophylactic agents. Nicotine,
its structural analogs, and other nAChR agonists are being looked at for possible
treatment catalyzed by the findings that there are a decreased amount of α4β2 subunits in
the brains of Alzheimer’s patients resulting in cholinergic deficits.22 The stimulation of
the α4β2 subunit with agonists exerts a neuroprotective effect against β-amyloids, the
neurodegenerative component in senile plaques.23 Interestingly, there is also a decrease
in incidence of Alzheimer’s disease amongst smokers.24
The neuroprotective effect of nicotine is also observed in Parkinson’s Disease- a
motor disorder characterized by tremors, rigidity, bradykinesia, and impaired reflexes,
which are caused by a loss of dopamine neurons in the brain. The ability of nicotine to
increase dopamine concentrations is what precisely brings about this effect.25 The
dopamine release is also seen as a therapeutic benefit for the treatment of Schizophrenia.
It is thought that Schizophrenics self-medicate with nicotine to increase their own
dopamine levels since nicotine potentially overcomes the effects of the dopamine
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antagonists commonly prescribed to Schizophrenics. This theory might explain why
there is an overwhelming number of Schizophrenia patients who smoke excessively.26
The sale of drugs to treat anxiety and depression generated over 20 billion dollars
in 2000.27 While nAChR drugs will probably never replace current selective-serotonin
reuptake inhibitor (SSRI) drugs (i.e. Prozac™), mood elevation was seen amongst major
depression patients after using transdermal nicotine over four days probably due to
serotonin and norepinephrine release.28 In addition to anti-depressive properties of
nicotine, smokers uniformly report a calming effect after a cigarette. The anxiolytic
effect of nicotine may be a result of receptor desensitization. This is evident when
desensitizing doses are continually administered and the anxiolytic activity remains.29
Though the anti-anxiety effects of nicotine analogs are much lower than that of the
benzodiazapines, they do not impair motor function or cognitive performance.
Nicotine addiction involves a myriad of physiological responses including
cognition enhancement, psychological conditioning, stress relief, withdrawal relief, and
other reinforcing properties. Some of these properties can be attributed to the
dopaminergic release system, but the oral fixation, hand-to-mouth coordination, and
social associations make curing nicotine addiction a daunting challenge. Nicotine itself
has had only modest success as a smoking cessation agent. Nicotine delivered via a gum
or transdermal patch does not produce the significant effects exhibited by inhaled
nicotine. Several nAChR agonists/antagonists are currently being studied for their
ability to substitute nicotine and block the reinforcement effects. (-)-Lobeline (3) has a
high binding affinity at the α4β2 subunit and it is currently in clinical trials as a smoking
cessation drug.30

12

O

N
Me

OH

(-)-lobeline 3

The modest, but definite, anti-nociceptive properties of nicotine were first
reported in the 1930s.31 More recently, injected nicotine has been thought to activate
pain inhibiting pathways and antinociceptive mechanisms via a process that appears to
involve calcium ions.32 The relatively short-lasting and modest efficacy of nicotine as a
pain-killer, coupled with its numerous side effects, will prevent nicotine from ever being
marketed as an analgesic agent. However, the discovery of the natural alkaloid, (-)epibatidine (4), which produces potent antinociceptive responses in rodents, has renewed
interest in a nAChR mediated painkiller. Epibatidine will be discussed in detail in future
sections.
The diverse possibilities for the subunits of the neuronal nicotinic acetylcholine
receptors give rise to a multitude of functions in the central nervous system. It is this
disparate activity that makes these receptors significant targets for a wide variety of
therapeutic agents. The characterization of functionally relevant subunit concentrations
in conjunction with their locations is necessary in order to identify potent and selective
ligands. Since no full three-dimensional structure has been mapped, the number of active
pharmacophores developed has increased drastically over the past ten years. These have
provided, and will continue to provide, the tools necessary for understanding the
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functional importance of nAChR subtype diversity. Consequently, the potential for
developing ligands for use in disorders such as Alzheimer’s Disease, Parkinson’s
Disease, anxiety and depression, schizophrenia, and pain management is encouraging.

Inhibition Constants and Effective Concentrations
Compounds are measured for their binding affinity for the nicotine receptor by
determining the concentration at which the compound displaces (or inhibits) 50% of a
radiolabeled ligand with known binding affinity. For example, [H3] nicotine or
[3H]cytisine can be used as the standard to measure binding affinity at the nAChR. The
concentration of prepared ligand required for the response is reported in molar units as an
IC50 value-the effective concentration. The usefulness of this value is limited due to
variances in technique and tissue samples between labs. Cheng and Prusoff derived an
equation (Equation 1) that incorporates the concentration of the ligand tested [L] and the
dissociation constant (Kd) of the standard compound from the receptor.33 This value is
reported in molar units as an inhibition constant (Ki). Inhibition constants are more
useful for comparison between labs.
Ki = IC50
[L]/Kd +1

(Eq 1)

Another measurement used to determine the potency of a ligand at a receptor is
the effective concentration (EC50). The EC50 of a compound is the concentration at
which the drug illicits 50% of the biological response seen when acetylcholine, the
endogenous neurotransmitter, is bound.
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Epibatidine
One of the most potent nAChR ligands discovered was originally isolated from
the poison dart frog Epipedobates tricolor in 1974 by Dr. John Daly.34 The compound
was originally identified from two populations of the E. tricolor in southwestern Ecuador
and termed 208/210 based upon mass spectrometry analysis. When the structure was
finally determined in the early 1990s to be [(1R, 2R, 5S)- 2-(2-chloro-5-pyridinyl)-7azabicyclo [2.2.1]heptane, epibatidine (4) became the topic of much research.

H
N

Cl
N

(-)-epibatidine 4

In a routine toxicity test, the alkaloid was injected into a mouse and the Straubtail response was observed. This is defined when a mouse arches its tail over its back in a
manner inherent to an opioid response. Rat tail flick assays showed that epibatidine had
incredibly potent antinociceptive properties 200 times that of morphine.35,36 The studies
also showed that the analgesic effect is mediated through neuronal nAChRs, not opioid
receptors, due to its inability to be blocked by the opioid antagonist naltrexone. The
analgesic effects of epibatidine, however, could be blocked by the neuronal nAChR
antagonist mecamylamine (5).37 The peripheral nAChR antagonist, hexamethonium (6),
which is incapable of passing through the blood-brain-barrier, had no effect on the
analgesic effects of epibatidine.38 The therapeutic effects of epibatidine, as well as its
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toxicity are both a result of its high binding affinity to the nAChR, which is in the low
picomolar range (Ki = 55 pM).34 This is approximately 300 times more potent than
nicotine at these receptors. Epibatidine will not, however, ever be developed as an
analgesic agent due to its very narrow therapeutic index. At concentrations only slightly
higher than those alleviating pain, severe hypertension, convulsions, respiratory
depression and death has been observed in animal models.36

NHCH3
CH3
CH3
CH3
mecamylamine, 5

2X+
(H3C)3N

+
N(CH3)3

hexametonium, 6

The idea of a potent analgesic agent that is not mediated by opioid receptors was
very exciting. While opioids, such as morphine, can be used successfully to treat
moderate to severe pain, there is a ceiling to their therapeutic effects for chronic pain.
Also, opioids have many undesirable side effects associated with their use including
severe constipation, respiratory depression, tolerance, and significant potential for
addiction.39 By discovering an analgesic agent mediated through the neuronal nAChR, a
whole new level of non-narcotic pain management therapy became possible.
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NH
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(-)-cytisine 7

For specific receptor subtype affinity, in vitro competitive binding studies were
preformed comparing (-)-epibatidine with [3H](-)-nicotine (1) and [3H](-)-cytisine (7),
agents known to be highly selective for the α4β2 subunit. Epibatidine displaced
[3H]nicotine with a Ki = 55 pM and [3H]cytisine with a Ki = 45 pM, lower concentrations
than any other compound used to date in this assay. Epibatidine (4) was also tested for its
affinity for the peripheral α7 subtype by a competitive binding assay with αbungarotoxin. The inhibition constant was calculated to be only 230 nM, thus
demonstrating the selectivity of epibatidine for the α4β2 subunit as well as a 20-fold
higher potency than nicotine at the α7 subunit.36,38 Even though epibatidine displays a
selectivity for neuronal subtypes over peripheral, it exhibits high binding affinity at
numerous binding sites throughout the brain of rodents.40 It has also been shown that
both enantiomers of epibataine offer high binding affinity, with the unnatural (+)
enantiomer only slightly less potant that the natural (-) enantiomer.38
Epibatidine was tested for its ability to stimulate dopamine release in rat brains
as compared to nicotine. Sullivan and his coworkers found that epibatidine has an EC50
of 0.4 + 0.1 nM versus 60 + 12 nM for nicotine. To implicate the α4β2 subunit, the
stimulated dopamine release by epibatidine was blocked by known antagonists to the
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receptor. 36 Epibatidine also stimulates the release of the neurotransmitter
norepinephrine. In this paradigm, epibatidine has an EC50 = 19.6 nM compared to 34.6
nM of nicotine. The lower potency observed for norepinephrine release relative to
dopamine release implies that a subunit other than the α4β2 is involved in norepinephrine
release.41

Structure-Activity Relationships of Epibatidine at the nAChR
In order to build a more complete pharmacophore model for the nAChR,
structure-activity relationships of biologically active compounds are studied to a great
extent. By comparing structure similarities of more potent compounds, better new
compound designs can be achieved. One of the first atructure-activity relationship
studies was of substituent effect on the pyridyl ring.
H
N

X
N

8a, X = H
8b, X = CH3
8c, X = F
8d, X = Br
8e, X = I

8f, X =NH2
8g, X = OH
8h, X = N(CH3)2
8i, X = CF3SO3

The 2-position on the pyridyl ring can tolerate a variety of substituents without
compromising the potency.36, 37 The analogs 8a-e bind to the α4β2 subunit with similar
affinity to epibatidine. The amino moity 8f was found to exhibit decreased binding
affinity with respect to epibatidine, but maintained a potency comparable to nicotine.
The 2-position was not tolerant of a hydroxy group 8g, a dimethyl amino group 8h, and a
triflate 8i as seen by lower binding affinities for these analogs.42
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Y
H
N

9a, X = Cl, Y = Cl
9b, X = Cl, Y = F
9c, X = Cl, Y = Br

X
N

9d, X = Cl, Y =I
9e, X = Cl, Y = NH2
9f, X =OH, Y = Br

The addition of an electron-releasing halogen substituents ortho- to the chlorine
atom of epibatidine resulted in ligands 9a-d with equipotent binding affinity to
epibatidine. Interestingly enough, the 3’-amino analog 9e was 26 times more potent than
[3H] epibatidine (Ki = .001 nM) at the α4β2 receptor subtype.43 This compound
displayed potent, but decreased affinity for the α7 subtype (Ki = 13.9 nM) with a Ki ratio
α4β2/α7 approximately 14,000—which is two times more selective than epibatidine in
this assay. Though the binding data proves 9e to be more potent as well as more selective
than epibatidine, it is not more efficacious. The compound did not produce the
analagesic activity of epibatidine with comparable EC50 (effective concentration) values.
More of the drug would be required to attempt reproducing the analgesic effects of
epibatidine, which may conflict with the toxicity levels of the compound. The 2-bromo,
3-hydroxy 9f was inactive in all analgesia tests. The endo isomer of epiatidine (10)
exhibits lower binding affinity than the natural exo isomer,44 as does the N-methylated
analog (11). However, the analgesic activity was not significantly diminished by
methylation.38
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Epiboxidine (12a), first synthesized in the Daly group, replaced the
chloropyridine ring with an isoxazole ring. The N-H compound proved to have only 10fold less binding affinity in rat-brain than epibatidine (Ki =0.6 nM) as well as a 10-fold
decrease in analgesic effects. It was, however, 10-fold less toxic than epibatidine in
mice. The biological properties of the methylated analog 12b corresponded to
methylated epibatidine in that it displayed a lower binding affinity than the desmethylated
epiboxidine.
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Some constrained analogs of epibatidine 13-16 synthesized in the Kozikowski
group recently provided some insight as to the relative positioning of the pyridine ring in
the receptor. The two spiro compounds 13 and 14 exhibited very low binding affinity
(with Ki in the µM range) for all subtypes tested including the α4β2. This was consistant
with other 2-endo epibatidine analogs. The fused ring compounds 15 and 16 exhibit high
binding affinities at α4β2 albeit, still significantly lower than that of epibatidine (α4β2 Ki
= 73, 295 nM, respectively). Even though similarities exist between the internitrogen
distances of the fused ring compounds (15, 16) and epibatidine, there is enough variation
to be discriminated by the receptor.45

21

Cl

H
N

H

H
N

N

N

N

X

H
19

18a, X = Cl
18b, X = H

17

R
N

O

N

N

R
CH3

N
O

20a, R = H
20b, R = CH3

N

21a, R = H
21b, R = CH3

CH3

The 8-azabicyclo[3.2.1]octane ring system homologs of epibatidine were
synthesized in our lab from 2-tropinone and 3-tropinone (17-19).46, 47 The endo and exo
chloropyridyl compounds 17 and 18a exhibited a 30-fold decrease in binding affinity for
the nicotine receptor as well as a 30-fold decrease in analgesic activity. This implied that
the rigid 7-azabicyclo[2.2.1]heptane ring system is necessary to maintain the high
binding of epibatidine. When the chlorine was substituted with hydrogen (18b), the
binding affinity was five-fold less potent than the chloro derivatives. Moving the pyridyl
group to the 3-position of the tropane ring also reduced the affinity (19). Epiboxidine
analogs 20-21 of the 2-tropane ring system were also synthesized in our labs. The 2β
analog 20a was to exhibit high affinity for the α4β2 subtype (Ki =3.3 nM).47
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The Structure-Activity Relationship of Nicotine Related Analogs
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Since the biological activity of nicotine has been known for some time, many
structurally related compounds have been synthesized and tested. The unnatural
enantiomer, (R)-nicotine (22), maintains potency at the nAChR, with only a 10-fold
decrease in binding affinity.48 A series of racemic 6-substituted nicotine analogs 23a-d
were synthesized to study the effects of electron-withdrawing and electron-releasing
groups on the aromatic ring.66 As compared to racemic nicotine, the halogens 23a, 23b
and the methyl group 23c did not effect the binding assay while the methoxy group 23d
decreased the binding. The halogens did increase the analgesic activity fifteen-fold in
tail-flick assays.
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SIB-1508Y (24) is presently being tested in patients with Parkinson’s Disease
after its high binding affinity was reported (Ki = 3 nM). The promise of drugs such as
these beckons scientists to create a better nicotinic pharmacphore model. The rigid
nicotine analog SIB-1926 (25) was created to achieve just that.49 While SIB-1926 did
produce an analgesic effect in mouse models, as well as stimulate dopamine release, it
was not as potent as nicotine at the native receptor.
After the discovery of epibatidine, NH compounds were looked at for the same
biophysical properties. The demethylated nicotine compounds were tested for their
potency and both enantiomers (26, 27) were less potent than nicotine. Also, replacing the
pyridine ring with phenyl (28) resulted in a 100-fold decrease in binding affinity.
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The pyridyl ring was replaced with an isoxazole moity to furnish ABT-418
(29). This compound maintained high binding affinity to the α4β2 subunit (Ki =4.2
nM).50 In addition this compound showed significant promise in the treatment of
Alzheimer’s disease as it increased the cognitive function of Alzheimer’s patients in high
doses.51 ABT-418 exhibits the cognitive and anxiolytic effects seen of nicotine, but in
the absence of many side effects associated with nicotine. This is a result of the greater
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selectivity ABT-418 has for the α4β2 subtype over the ganglionic α7, as compared to
nicotine.52 As seen in the paradigm for nicotine, the (S)- enantiomer (29) is more potent
than the corresponding (R)-enantiomer (30).16 Placing the isoxazole ring at the
bridgehead position of the rigid 7-azabicyclo[2.2.1]heptane ring system (31a, 31b)
decreased the activity greatly.53

Structure-Activity Relationships of Pyridyl Ethers
Though many potent ligands for the nAChR have been developed, most were not
as subtype selective as a therapeutic agent should be. Nor did they contain a high
thereputic index (defined as the range between the biologically effective concentration
and the concentration at which the compound is toxic). A series of 3-pryidyl ethers
developed by Abbott Laboratories marked a new breakthrough in nicotine receptor drugs.
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In 1996, Holladay et al. synthesized a series of methylated and desmethylated
pyrrolidine and azetidine rings with 3-pyridyl ether functional groups. The (S)pyrrolidine enantiomer, A-84543 (32a), and both desmethyl analogs 32b, 33a showed
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sub-nanomolar binding affinity at the α4β2 nicotine receptor (Ki = 0.15, 0.16, and 0.14
nM, respectively).54 The methylated (R)-pyrrolidine enantiomer 33b showed a 100-fold
decrease in binding activity. Even more promising was their selectivity for α4β2 when
compared with another central nervous system subtype (α3βx).
The ring reduction to an azetidine offered a new structural class of nicotinic
agonists 34-35. These compounds followed the trend of the pyrrolidine analogs, with the
N-methylated (R)-enantiomer 35a showing a lower binding affinity than the others in the
series, albeit still in the nanomolar range.54 The desmethylated compounds 34b, 35b
exhibited Ki values in the picomolar range—similar to epibatidine—as well as similar
EC50 values. The EC50 values were 160% greater than that of nicotine. Unfortunately,
these compounds are 20-40-fold less potent than epibatidine to activate the receptor.
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These findings led to the exploration of substituted derivatives as well as the
nature of recognition with respect to the ether linkage.55 The 2-methyl pyridine ring 3637 analogs paralleled the non-methlyated versions with all compounds exhibiting
nanomolar binding with the exception of the (R) enantiomer 37b which exhibited greatly
decreased binding affinity. In addition to high binding affinity, 36, 37a showed
substantial selectivity over the ganglionic α7 subtype. The derivative ABT-089 (36a),
with Ki = 16 nM, is also orally bioavailable with reduced degradation in liver
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metabolism. Activity characterization studies were preformed in an aged primate model
and cognitive enhancing properties were observed as well as anxiolytic properties.54
The ether linkage and chain length of 36-37 appear to be crucial for high
molecular recognition. The sulfur derivative 38a exhibits a 2000-fold decrease in
binding affinity relative to the oxygen analog 38a. Removal of the electronegative
element altogether 38b decreased the binding by 150-fold. If the ether linkage is
removed from the pyrrolidine ring by an ethylene linkage versus a methylene 38c, a 120fold decrease is also seen.56 Finally, if the pyridine ring is replaced by phenyl, the high
binding affinity is lost.57
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The 6-chloro-analogs 39-43 of the Abbott Laboratory pyridyl ethers were
synthesized for comparison to epibatidine 58 All of the chlorinated ethers in this series
bound to the α4β2 subunit at picomolar concentrations, with the exception of 40 and 42.
In addition to equipotent binding affinity to epibatidine, ABT-594 (39) also exhibited the
same level of orally active analgesia. A more significant feature of ABT-594 (39) is that
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it had a much lower toxicity and is more selective for the α4β2 subtype over the α7.
The higher therapeutic index and lower risk of side effects brought ABT-594 (39) though
Phase II and Phase III clinical trials as a pain-killer. For the pyridyl ether series of
compounds, it is clear that the pyridine ring and the 6-chloro substituant are major factors
in the high binding affinity/low toxicity/high selectivity properties displayed.
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Various conformationally constrained analogs 44-46 have been synthesized to
study the possible conformation geometry in the binding site.59 Though the 2azabicyclo[2.2.0] hexane rings retained nanomolar binding affinity for the neuronal
nAChR, their EC50 values were between 11-34% of the maximum response (46<44<45).
These compounds were also less effective than epibatidine and ABT-594 in producing
analgesic activity. This shows that the conformation adopted by ABT-594 probably does
not resemble 44 or 45.
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Recently in our labs, 2-substituted rigid 7-azabicyclo[2.2.1]heptanes 47-49 were
synthesized.60 All compounds showed a lower binding affinity than epibatidine and
nicotine, with the endo 47a-c exhibiting low to moderate micromolar concentrations as
well as the deschlorinated exo compounds 48a, 48c. The exo 6-chloropyridine 48b
offered the best binding, in the submicromolar range, and though still too low for potent
therapeutic use, the structure-activity relationships of the ethers were consistent with
those of epibatidine and its analogs. The 2-pyridyl derivatives 47c, 48c and the amide
analog 49 did, however, display comparable potency to the 3-pyridyl homologs, which
had not been seen in other series. With the ether linkage in the 2-position of the bicyclic
system, the 7-azabicyclo[2.2.1]heptane ring does not substitute for the azetidine ring as
recognized by the α4β2 receptor.
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Structure-Activity Relationship of N-substituted Bicyclic Rings
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Also synthesized in our labs were a series of N-substituted and N-tethered 7azabicyclo[2.2.1]heptane ring derivatives 50-53.61, 62 All of these compounds displayed
decreased binding affinity when compared to epibatidine, nicotine, and cytisine. The Naryl derivatives 50a-c only displayed 50% inhibition of [3H]Cytisine at 100 µM
concentrations. The N-methylene-aryl derivatives were also poor nAChR activators, with
the 3-pyridyl analog 51c, being by far the most active, with a Ki of approximately only
100 nM. Increasing the tethered chain to an ethylene 52 and a propylene 53 decreased
the binding accordingly.
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The Nicotine Receptor Pharmacophore Model
A pharmacophore can be defined as a “minimal ensemble of structural features
common to a series of agents, seemingly responsible for a specific effect.”63 Specifically,
a pharmacophore for the nAChR should possess the physiochemical properties necessary
to stimulate activity at the receptor. There is a long history of research groups proposing
pharmacophore models for the nicotine receptor dating back to 1952.
The first pharmacophores were based on the internitrogen distance of nicotine and
structurally similar acetylcholine. The most recent and accepted theories were devised
starting in 1970 when Beers and Reich advanced their previous studies using Dreiding
and CPK space filling models.64 They found two common structural features necessary
for nicotinic agonist and antagonist activity: a couloumbic interaction involving an
alkylammonium moiety and an H-bond that depends upon an acceptor 5.9 Å away from
the center of the positive charge (Figure 4).64 The internitrogen distance, however is 4.85
Å, a consistent measurement with earlier models.
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Figure 4: The Beers and Reich Pharmacophore Model64
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Sheridan extrapolated the Beers and Johnson model to essentially describe a
pharmacophore with an H-bond acceptor and a more basic nitrogen in the molecule that
can become protonated and likewise became a center of positive charge. They also noted
a distance of 1.2 Å between the H-bond acceptor and a third atom that resides above the
plane of the internitrogen space.65 This model, based on nicotine, cytisine, and
ferruginine, corresponds with Beers and Reich distance of 5.9 Å between the onium site
and the van der Waals surface (Figure 5).64, 65
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Figure 5:Comparison of the Beers and Reich Pharmacophore with the Sheridan Model.63
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Glennon and coworkers added to the pharmacophore requirements a stipulation
on the basic nitrogen substituents. A series of simple aminomethylpyridines 54-55 were
synthesized where the internitrogen distance did not vary greatly amongst analogs.
Nevertheless, the pharmacology changed greatly. The disubstituted nitrogen (R1= Me,
R2= Et) bound much higher (Ki= 28 nM) than the primary amine (R1= R2= H) whose
inhibition constant was greater than 10,000 nM.66
The discovery of epibatidine (4) offers exception to an industry standard.
Although there are some structural similarities, there are some obvious differences.
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Even though the two structures are superimposeable, the internitrogen distance of
epibatidine is 5.5 Å instead of the 4.97 Å seen in nicotine. This distance is longer than
both the previous models and would seem to predict a low affinity for the receptor. On
the contrary, epibatidine has one of the highest affinities for the nAChR known to date.
Glennon and coworkers proposed a new model in 1994 with the optimum internitrogen
distance of 5.1-5.5 Å taking into account the structure of epibatidine. A reasonable
structural resemblance between epibatidine and nicotine can be seen through overlapping
the basic and pyridinium nitrogens of each (Figure 6).

Figure 6: Epibatidine (red) and nicotine (blue). Nitrogen atoms in dark blue overlap.67

In 1996 Abbott Laboratories based molecular modeling studies on their series of
pyridyl ether compounds (39-43) known to have potent nicotinic agonist activity. They
found the optimum internitrogen distance for ligand receptor interaction to be 6.1 Å.68
Obviously, much work is still needed to identify concrete nicotinic pharmacophores. To
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date no pharmacophore model has been successful in incorporating all active nAChR
ligands. However, with every new active class of compounds, the picture of a nicotinic
pharmacophore becomes potentially more clear.

Rigid Acetylcholine Analogs
The nicotinic acetylcholine receptors are responsible for recognition and binding
of the neurotransmitter, acetylcholine (2). The junction at which neurons pass signals to
other neurons, muscles, or glands are called synapses. In these synapses, the arriving
action potential triggers the release of a neurotransmitter from the presynaptic neuron
which diffuses across the cleft and binds to its corresponding receptor on the postsynaptic
membrane. Neurotransmitter binding stimulates membrane depolarization, thereby
triggering an action potential on the postsynaptic membrane.69
Acetylcholine binds to the receptor activating the ligand gated ion channel and
stimulating the central and parasympathetic nervous system. Its transmission plays a role
in numerous physiological functions including stimulation of the vagal nerve that
decreases the heart rate and cardiac output, dilation of blood vessels to decrease blood
pressure, stimulates gut motility, stimulates genitourinary smooth muscle, and regulates
muscle constriction.70
Those compounds that are active at these receptors, as agonists or antagonists, are
of particular interest in treating several central and peripheral nervous conditions such as
Parkinson’s disease, Alzheimer’s disease, Tourette’s syndrome, myasthenia gravis, and
depression-anxiety disorders. Some common natural agonists, including acetylcholine,
nicotine, and epibatidine, and antagonists as hexamethonium, succinylcholine, and α-
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bungarotoxin are commonly used as models in current drug synthesis. An agonist is a
drug that increases or decreases the activity of the particular cell with which the receptors
are associated versus an antagonist which counteracts or prevents the action of another
drug or endogenous body chemical.
Acetylcholine is a flexible molecule with many possible conformations. The
topography of the ion-channel of the acetylcholine receptor is not fully known. Likewise
the binding conformation of acetylcholine is unknown. By constructing several rigid
conformations of acetylcholine and its derivatives, a better understanding of its spatial
geometry within the receptor, and ultimately the three-dimensional receptor structure can
be achieved.
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The tropane ring system has been studied for its binding capabilities at the
nicotine receptor. A series of 3-phenyl tropane rings 56-59 were synthesized and tested
for their effects on blood pressure in dog models.71 All increased the blood pressure at or
near the levels of nicotine, with the exception to 59, which was inactive. Though less
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toxic than nicotine, there was still a modest therapeutic index. Also, the drugs caused
convulsions, respiratory depression, and death.
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In 1962, Archer72 had made 2-acetoxy-tropane derivatives 60 and 61. These
quaternary 2-acetoxy-tropane isomers were found to mimic acetylcholine. They
activated the ligand gated ion channel and ultimately stimulated the parasympathetic
nervous system, but only preliminary biological studies were performed.

Specific Aims and Design Strategy of Epibatidine Analogs
New compounds that incorporate the chloro pyridyl group of epibatidine tethered
to a nitrogen containing ring via an ether linkage have proven to have similar potencies as
that of epibatidine at the nAChR. These compounds have potential as analgesic agents
because of significant decrease in toxicity. Though encouraging, none of these pyridyl
ethers have yet been viable drug candidates for either pain control or central nervous
disorder treatment. To this end, a series of pyridyl ether derivatives have been envisaged
to explore the structure-activity relationship of epibatidine related compounds. The
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derivatives were designed to be hybrid structures of epibatidine and ABT-594 (Scheme
1). In this series, we will study the effects of the bridgehead substituted ring system on
the proximity of the basic and pyridyl nitrogen. Attaching a heteroaromatic ring onto the
rigid system with the nitrogen in varying positions will fine-tune our understanding of the
nAChR binding site.
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The synthesis of 1-substituted 7-azabicyclo[2.2.1]heptane ring system analogs
will exploit chemistry previously developed for epibatidine. An intramolecular ring
closing reaction will be employed to generate the 7-azabicyclo[2.2.1]heptane ring system.
The appropriately functionalized cyclohexane derivative will be prepared via a
stereoselective reduction of a functionalized cyclohexanone. The cyclohexanone can be
afforded through a [4+2] Diels-Alder cycloaddition between a diene and appropriately
substituted dienophile (Scheme 2).
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Specific Aims and Design Strategy of Rigid Acetylcholine Derivatives
The second specific aim is to study the binding conformation of acetylcholine at
the active site of the nAChR. To this end, a series of rigid 2-acetoxytropane analogs will
be prepared. Demethylated forms of the acetylcholine moeity will also be synthesized, as
many bicyclic N-H compounds, such as epibatidine, show potency at the nicotinic
acetylcholine receptor.
The 2-acetoxy tropanes 70-75 will be prepared by converting the corresponding
2-tropinol alcohols 76-77 into acetates.73 The chiral alcohols will be synthesized
stereoselectively from (R)-2-tropinone obtained by degradation from (-)-cocaine.74 The
individual α- and β- stereoisomers will be tested for binding affinity at the nicotinic
acetylcholine receptor in several assays.
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Natural Product Synthesis: (S)-Anabasamine
During the past decade, over 12,000 compounds containing a piperidine ring have
been employed in various stages of clinical trials.75 Efficient synthesis of piperidine
based compounds is of particular interest to medicinal chemists. Naturally occurring
alkaloids that incorporate piperidine and pyrrolidine rings have already been proven to
possess important biological activities.
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(S)-Anabasine (78), and (S)-anatabine (79) are found in the plant Nicotina
tobaccum, the species most prominently used in cigarette tobacco, and are quite potent at
the nAChR.16 Anabasine (78) has a 30-fold lower affinity for mouse brain than nicotine
and 40% the efficacy. It has a Ki of 210 nM at the α4β2 subunit. Anatabine exhibits
approximately half the potency of anabasine. Anabaseine (80) a paralytic toxin found in
the marine worm Paranemertes peregina, is a partial agonist at the α4β2 subunit. It
possesses a 20-fold weaker affinity for the α4β2 subunit when compared to nicotine and
only 10% the efficacy. It does, however, show high efficacy at the ganglionic α7
subunit, and therefore exhibits selectivity for this receptor subtype.16
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The analog of anabaseine, GTS-21 (81), has been tested in clinical trials and
shown to have positive effects on cognition in rats and rabbits. It has also exhibited
cytoprotective effects on learning and memory and against β-amyloids toxicity, the
plaques associated with Alzheimer’s Disease. The analogs 82 and 83 had lower binding
affinities than GTS-21 and did not exhibit the same level of therapeutic benefits.16
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A related alkaloid, (S)-anabasamine (84), is found in the poisonous semi-shrub
Anabasis aphylla of Central Asia.75 Limited preliminary studies on the biological effects
of anabasamine were conducted during the 1980s in the Soviet Union.76 Only recently,
anabasamine was shown to inhibit the catalytic activity of the enzyme
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acetylcholinesterase, which causes the rapid hydrolysis of acetylcholine at the nerve
synapse.77
When anabasamine was administered orally to rats, anti-inflammatory activity
similar to indomethain was observed.78 It also inhibited the inhibitory effects of steroids
such as hydrocortisone.79 This effect appears to be a result of activation of the adrenal
cortex-hypothalamus-pituitary system. The piperidine alkaloid may also strengthen the
adrenergic system as it reduces the ptosis caused by reserpine, a compound that blocks
the dopamine-norepinephrine transformation in mice.79
Another interesting discovery is that anabasamine was found to increase the
activity of hepatic alcohol dehydrogenase and proportionally decrease ethanol levels in
the blood stream of rats.80 It also stimulated the adrenal regulated production of
tryptophan pyrrolase in the liver of rats when administered.81
Most of the studies found on (S)-anabasamine (84) revolve around how to isolate
and purify the compound from the other alkaloids found in the plant specimen. The
limited concentrations in plants as well as difficulty in isolation make this compound an
attractive target for synthesis. Further studies of anabasamine as well as its analogs could
be conducted with greater ease if a more practical source of the compound were available
to scientists.

Specific Aims and Design Rational of Anabasamine
The specific aim of this research is to develop a short, practical, and efficient
synthesis of the plant alkaloid, anabasamine (84) and related nicotine analogs. The
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tricyclic compound will be synthesized as a racemic mixture. The racemate will then be
tested at the nAChR for binding affinity.
The synthesis will employ a Suzuki aromatic ring coupling of 3-pyridine boronic
acid to the 2-chloropyridine derivative 85 to afford anabasamine (84). The chlorinated
pyridine 85 will be prepared via chlorination of the aryl ether 86. The piperidine moiety
of the bicyclic compound 86 will be prepared through reductive amination of the ketoaldehyde 87. The corresponding alcohol will be prepared via an addition of δvalerolactone (89) to the 2-methoxypyridyl anion derived from commercially available 5bromo-2-methoxypyridine (90) (Scheme 4).
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Scheme 4

In a similar synthetic scheme (Scheme 5), the nicotine analog of anabasamine 91
will be prepared via the Suzuki coupling reaction of 3-pyridineboronic acid and 6-

45

chloronicotine (92). 6-Methoxynicotine (93) will be prepared via reductive amination of
the 4-oxo-butanal 94. The corresponding alcohol will be afforded through an addition
reaction of a pyridine anion to γ-butyrolactone (95). In this synthetic route, the common
drug intermediate 6-methoxynicotine (93) will be prepared in three steps.
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RESULTS AND DISCUSSION
Synthesis 1-(Pyridyloxymethyl)-7-aza-bicyclo[2.2.1]heptanes
Attempted Synthesis with Acetyl Protecting Group
Several synthetic routes were attempted to prepare a 1-substituted [2.2.1] bicyclic
ring system. The first route investigated was designed to incorporate the commercially
available Danishefski’s diene (67) with commercially available dienophile, methyl 2acetamidoacrylate (97), in a method proven successful to make monocyclic rigid proline
analogs.82 Scheme 6 illustrates the Diels-Alder cycloaddition using an excess of the
diene 7 (2:1 ratio) to the dienophile 97 and the components were stirred under an
atmosphere of nitrogen in refluxing toluene for 3 days. This furnished the cycloaddition
adduct that was directly carried on to the next step. After hydrolysis of the trimethylsilyl
group of 98, the elimination of the methoxy moiety of 99 was performed to yield the
enone 100 in 34% yield over the three steps. The enone 100 was then hydrogenated (H2,
1 atm) over palladium on carbon to afford the 4-substituted cyclohexanone 101 in 90%
yield.
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With the ketone 101 in hand, a selective reduction was performed on the
cyclohexanone employing the bulky borohydride reagent, L-Selectride ® (lithium tri-secbutylborohydride). The adjacent axial hydrogen atoms prevented the indiscriminant
reduction of the carbonyl by the bulky reagent from either face. This procedure furnished
a 9:1 ratio of the trans-cyclohexane derivative 102 over the cis configuration 103 as
determined by NMR peak integration of the methyl ester peaks (Scheme 7). The isomers
were not separated at this time.
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The work up of the L-Selectride reduction proved to be very important. The
borohydride reagent was quenched with saturated ammonium chloride and the THF was
removed under reduced pressure on a rotary evaporator. When heat was used to aid in
the THF evaporation in the presence of the aqueous acid, the major product that was
obtained resulted from intramolecular cyclization to furnish the bicyclic lactone 104 in
94% yield. The formation of 104 served to confirm the relative stereochemistry of the Lselectride reduction of ketone 101. Only the trans isomer 102 could form the bicyclic
lactone 104. The problem of intramolecular lactone formation was corrected by filtration
of excess precipitated ammonium chloride followed by a solvent evaporation under
reduced pressure at temperatures no greater than 40 °C.

O
O

H
N

Ac

104, 94%
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The isomeric alcohols 102 and 103 were converted into their corresponding
mesylates with mesityl chloride. Separation of the mesylate isomers by gravity column
produced the pure trans-1, 4-disubstituted cyclohexane derivative 105 appropriate for an
intramolecular ring closing transformation. With the mesolate 105 in hand, the ring
closure was attempted (Scheme 8). With potassium tert-butoxide, the 7azabicyclo[2.2.1]heptane 106 was only formed in poor yield (15%). This was due to the
acetyl protecting group being a poor electron- withdrawing group and likewise, rendering
the hydrogen atom on the nitrogen atom less acidic. As a result, the proton was not
acidic enough to facilitate the ring closing reaction.

MsO

H

H3COOC

N
H

KtBuO, THF

Ac
N COOCH3

Ac
15%

105

106

Scheme 8

Attempted Synthesis with Toluenesulfonyl Protecting Group
An alternative protecting group was sought that would provide sufficient proton
acidity. For this, the p-toluenesulfonyl group was chosen. The corresponding acrylate
dienophile was not commercially available. The attempted synthesis from the
inexpensive reagent, d,l-serine methyl ester hydrochloride (107) is illustrated in Scheme
9. The amino and the hydroxyl groups were converted simultaneously into the sulfamide
and tosylate in one step using an excess of p-toluenesulfonyl chloride in the presence of
triethylamine (Scheme 9). After removing excess unreacted p-toluenesulfonylchloride,
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the resulting oil was used without purification in a DBU (1,8-diazobicyclo[5.4.0]undec-7ene) mediated elimination reaction. The elimination to the corresponding acrylate 108
was not successful. Despite using various bases, reaction temperatures, and solvents, the
desired acrylate was never obtained. Trace amounts of starting material were recovered,
but mostly intractable decomposition products were observed.

NH2

HO

CO2Me

HCl 1) TsCl, TEA, CH2Cl2
2) DBU, CH2Cl2

107

H3COOC

N
H

Ts

108

Scheme 9

Stepwise tosylation of the nitrogen followed by tosylation of the alcohol moiety
was performed to ensure that the proper intermediate was formed (Scheme 10). The
desired sulfamide 110 was made by treating L-serine (109) with an excess of sodium
carbonate in water. This afforded the N-tosyl serine 110 in 84% yield. The carboxylic
acid moiety was converted into the corresponding methyl ester 111 by refluxing in HClmethanol in 94% yield. Tosylation of the alcohol employed pyridine as a base and gave
only modest yields (46%) of the desired tosylate 112. With the alcohol converted into the
tosylate and the nitrogen protected appropriately, the desired DBU mediated elimination
to the acrylate dienophile was attempted. Despite numerous attempts and varied reaction
conditions, the desired acrylate 108 was not obtained.
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The same sequence was followed for the preparation of a mesylate leaving group
113 in an attempt to produce the elimination product 108 (Scheme 11). A multitude of
different bases and conditions were explored (DBU, pyridine, sodium hydroxide,
triethylamine, 1,4-diazabicyclo[2.2.2]octane, tetrabutylammonium fluoride, potassium
tert-butoxide), however none of which resulted in the desired acrylate The reason the
elimination product 108 was not obtained is envisaged to be due to the competing
azetidine ring formation 114 and subsequent decomposition. Though this compound was
never characterized by NMR due to its instability, this is predicted based on the relative
reactivity of the N-hydrogen atom vicinal to the tosyl group.
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Attempted Synthesis with tert-Butoxycarbonyl Protecting Group
Even after attempts to trap the dienophile 108 during its formation by placing it in
excess diene 67, it was clear that the protecting group was poorly suited for this task.
The tert-butoxycarbonyl (Boc) group, a less electron-withdrawing protecting group, was
utilized (Scheme 12). Commercially available N-t-butoxycarbonyl-d-serine methyl ester
(115) was converted into the corresponding tosylate utilizing the procedure of Boggs, et
al.83 Upon recrystallization, the white solid 116 was obtained in 75% yield. This was
subsequently subjected to the DBU (1,8-diazobicyclo[5.4.0]undec-7-ene) mediated
conditions to give the desired acrylate 117 in 98% yield.84
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With the Boc-protected dienopohile 117 in hand, the Diels-Alder [4+2]
cycloaddition was studied. 2-Trimethylsiloxy-1,3-butadiene (118) was selected as the
diene in order to minimize the number of steps in the synthesis, but this proved not to be
as successful in the Diels-Alder cycloaddition as Danishefsky’s diene[1-methoxy-3(trimethylsilyloxy)-1,3-butadiene] (67) (Scheme 13). Even when the Lewis Acid catalyst
ZnI2 was employed, the results were not as favorable as when the methoxy group was
present on the diene. The best results were obtained when one equivalent of the
dienophile 117 was heated with four equivalents of Danishefksi’s diene (67) in refluxing
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toluene under an atmosphere of argon for 24 hours, at which time 1 more equivalent of
the dienophile was added and the mixture was heated to reflux for an additional 48 hours.
The excess diene was necessary to discourage the dienophile from reacting with itself.
This was immediately followed by hydrolysis of the trimethylsilyl group to afford the
ketone 119 (Scheme 14).
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The same procedures (Scheme 14) were preformed to eliminate the methoxy
group of 119 as employed for 99. The absolute purification of the enone 120 became and
important step in the procedure. After gravity silica gel column chromatography using a
gradient solvent system of pure chloroform gradually increasing to 10% methanol:90%
chloroform, a single compound was obtained. The H1 NMR showed only a slight
impurity. However, the compound was a very viscous oil. This made the compound
very difficult to handle in subsequent steps. The enone 120 was then hydrogenated over
10% palladium on carbon in methanol to furnish the ketone 121. Following the
hydrogenation, filtration of the catalyst through Celite®, a fritted funnel, or even filter
paper became almost impossible owing to the viscosity of the compound.
Recrystalliazation of the enone in a 3% MeOH solution in chloroform offered absolute
purity and a yellow crystalline solid in 60% yield.
Selective reduction of the ketone was again achieved with L-Selectride to afford
the alcohol 122 in 77% yield without the complication of the lactone formation. The Boc
group was converted into the tosyl group in order to prepare the molecule for a
Mitsonubu ring closing reaction. Attempts to remove the Boc group with trimethlysilyl
iodide caused cleavage of the methyl ester and standard conditions employing
trifluoroacetic acid resulted in dehydration of the alcohol to the corresponding
cyclohexene. The amino group was successfully deprotected to afford the quaternary
ammonium salt 123 by HCl/methanol/ethyl acetate that was generated from acetyl
chloride and methanol. The ammonium salt 123 was dissolved in a solution of potassium
hydroxide, p-toluenesulfonyl chloride, and triethylamine. This furnished the sulfonamide
124 in a modest 55% over two steps (Scheme 15).85
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The p-toluenesulfonyl protecting group had recently been reported in the literature
to facilitate an intramolecular Mitsonubu ring closure where other protecting groups
failed. This reaction occurs in the presence of diethyl azodicarboxylate (DEAD) and
triphenylphosphine (PPh3).62 However, no Mitsonubu ring closures have been reported
where a functional group was attached to the same carbon as the protected amine. To our
dismay, the Mitsonubu cyclization gave only very poor yields (18%) of the desired 7azabicyclo[2.2.1]heptane derivative 125. A small amount of starting material was
recovered along with numerous intractable side products after reaction times of 48 hours.
In order to facilitate the ring closure, the alcohol 124 was converted into the
mesylate leaving group 126 (Scheme 16). Potassium tert-butoxide mediated
intramolecular cyclization also did not afford enough of the 7-azabicyclo[2.2.1]heptane
125 to generate the desired analogs (Scheme 16).
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Synthesis Employing Benzoyl Protecting Group
At this point, a modified procedure used to study rigid proline analogs was
employed to obtain higher yields of the necessary intermediate (Scheme 17).86 If the
literature procedure was followed, for the one-pot benzoyl protection of the amine as well
as the alcohol of d,l-serine methyl ester (126), a poor yield was obtained of the desired
product 127. The yield was improved over the reported literature value by adding the
reagents to the salt slurry at 0 ºC instead of 25 ºC. Also, adding the benzoyl chloride
(BzCl) and the triethylamine (TEA) in alternating portions of TEA followed by BzCl
prevented the reaction mixture from becoming too hot. This sequence was repeated until
the complete volume of each reagent was added. At that point the reaction was stirred at
room temperature until no starting material was apparent by thin layer chromatography
(TLC). The resulting yellow solid was triturated with hexanes to afford the white,
crystalline benzyl-amino acid derivative 127 in almost quantitative yield.
The subsequent elimination of the benzoate moiety of 127 was achieved by slow
addition of 1,8-diazobicyclo[5.4.0]undec-7-ene (DBU) to the stirred solution of 127. If
the temperature did not exceed 5 ºC, the dienophile 128 was furnished in 99% yield.
Removal of the solvent was achieved under reduced pressure at room temperature. If
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heat is applied, the resulting product will be a viscous, insoluble gel that was very
difficult to work with and produced significantly lower yields if used in the cycloaddition
reaction. Also, it should be noted that the dienophile should be used in the subsequent
cycloaddition as soon after its synthesis as possible, as it can transform into the viscous
material upon standing, even in the refrigerator, over time. This material generally gave
lower yields of the cycloaddition adduct 129.
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Utilizing 2-trimetyhylsiloxy-1,3-butadiene would be preferable in the Diels-Alder
[4+2] cycloaddition as it alleviates two time consuming steps. However, its limited
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availability eliminated the diene as a precursor in the synthesis. Danishefsky’s Diene (1methoxy-3-(trimethylsilyloxy)-1,3-butadiene 67) was an acceptable alternative being
sufficiently activated with electron-donating groups to facilitate the cycloaddition with
the acrylate dienophile 128. The diene and the dienophile were heated in toluene to give
the cycloaddition adduct 129 (Scheme 8) in 3-4 days. The trimethylsiloxy group
hydrolysis and elimination of the methoxy group were carried out as previously described
to afford the enone 131 in 70% yield over three steps (Scheme 18). The enone 131 was
hydrogenated over 10% palladium on activated carbon in methylene chloride to afford
the 4-substituted cyclohexanone derivative 132 in 95% yield.
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The cyclohexanone derivative 132 was selectively reduced with LSelectride (lithium tri-sec-butylborohydride) to produce the inseparable alcohol isomers
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133 and 134 (9:1) (Scheme 19). The dropwise addition of the borohydride reagent over 1
hour at -78 ºC followed by vigorous stirring at –78 ºC for 20 hours afforded the highest
yield of 86%. The isomeric alcohols 133 and 134 were converted into their
corresponding mesolates 135 and 136 in high yield. Separation of the mesylate isomers
by gravity column chromatography afforded the produced a pure trans 1,4-disubstituted
cyclohexane derivative 135 in 78% isolated yield. Potassium tert-butoxide was added to
the trans cyclohexane derivative 135 at –78 ºC and the solution was stirred for 1 hour at
this temperature. The reaction was then allowed to stir overnight at room temperature to
furnish the 7-azabicyclo[2.2.1]heptane ring 137 in 67% yield (Scheme 19).
MsO H

H Br
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If the conversion of the isomeric alcohols 133 and 134 into the corresponding
mesylates 135 and 136 in Scheme 19 was performed on a large scale, a significant
quantity of the cis cyclohexane derivative 136 was obtained. With the cis-mesylate 136
in hand, an attempt to convert it into the desired bicyclic intermediate 137 was made
(Scheme 20).87 Substituting the mesylate with bromine would afford a bromo-
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cyclohexane derivative 138 with the appropriate stereochemistry for the intramolecular
cyclization. However, treatment of the cis-mesylate 136 with lithium bromide and heat
only furnished the cyclohexene 139 as the major product.
Bz
N COOCH3
LiBH4, THF
25 °C
137

Bz OH
N

140 (58%)

Scheme 21

An attempt to reduce the methyl ester moiety of 137 to the primary alcohol 140 in
the presence of a benzoyl protecting group was made. The addition of lithium
borohydride in refluxing tetrahydrofuran (THF) resulted in the consumption of the
starting material within several hours, however a negligible amount of the desired
product was obtained.60 A variety of temperatures were tested, but even moderate
temperatures (e.g. 40 °C) produced a significantly lower yield than if the reaction
proceeded at room temperature (Scheme 21). Unsuccessful methods employed include
refluxing the ester in diethyl ether as well as in THF at 32 ºC. The highest yields were
obtained when 1.5 equivalents of lithium borohydride was added initially to the stirred
reaction with an additional 0.5 equivalents added every 12 hours until a total of 2.5
equivalents were added.
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Other reducing methods were attempted to increase the yield of the bicyclic
alcohol 140 (Scheme 22). The careful stoichiometric addition of lithium aluminum
hydride in THF reduced the benzamide protecting group concurrently with the ester
resulting in a side product that did not contain the benzoyl functionality. The by-product
proposed is the secondary amine 142, which was not isolated due to possible water
solubility. The deactivated lithium aluminum hydride in the presence of silica gel (SiO2)
was also attempted with no observed reduction to the desired alcohol 140.88 This bulky
reagent complex 141 is thought to be too sterically demanding to react with an ester on
the hindered bridgehead position.
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The bicyclic alcohol 140 was converted into the corresponding mesylate 143 with
methanesulfonyl chloride and triethylamine (Scheme 23). It is important to note that the
mesylate 143 cannot be purified by column chromatography, as decomposition readily
occurs. For this reason it was used in its crude form in the following Williamson ether
synthesis with hydroxypyridine derivatives 144-146. 3-Hydroxypyridine (144) and 2hydroxypyridine (145) are commercially available while 2-chloro-5-hydroxypyridine was
synthesized according to the literature procedure.89 As illustrated in Scheme 23, sodium
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hydride (NaH) was stirred in dimethylformamide under an atmosphere of nitrogen with a
corresponding hydroxypyridine 144-146 in dry dimethylformamide for 1 hour at room
temperature to generate the alkoxide ion from the alcohol moiety. The mesylate 143 was
then added to the alkoxide and the solution was stirred at 80 ºC until the ether formation
was complete (TLC). The reaction of the mesylate 143 with 3-hydroxypyridine (144)
afforded the 3-pyridyl ether derivative 147 in high yield (94%). The reaction of the
mesylate 143 with 2-hydroxypyridine (145) furnished the 2-pyridyl ether 148a in
moderate yield (51%) and the 2-pyridone side product 148d in 12% yield. This is the
result of a tautamerization that readily occurs in 2-hydroxypyridine. The pyridone 146d
was characterized by NMR and X-ray crystallography (Figure 7). The reaction of the
mesylate 143 with 2-chloro-5-hydroxypyridine (146) furnished the 2-chloropyridyl ether
149 in high yield (93%). The chlorinated ether structure was unequivocally established
by X-ray chrystallography (Figure 8).
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Figure 7. ORTEP Drawing of 1-(7-Benzoyl-7-aza-bicyclo[2.2.1]hept-1-ylmethyl)-1Hpyridin-2-one (148b). (Courtesy of E. D. Stevens and Z. Moore, University of New
Orleans)
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Figure 8. ORTEP Drawing of [1-(6-Chloro-pyridin-3-yloxymethyl)-7-azabicyclo[2.2.1]hept-7-yl]-phenyl-methanone (149). (Courtesy of E. D. Stevens and Z.
Moore, University of New Orleans)
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Deprotection of the benzamide was attempted several ways (Scheme 24).
Converting the amide directly into a secondary amine with diisobutyl aluminum hydride
(DIBAL-H) in toluene at –78 ºC was attempted.90 However, when this procedure was
applied to the pyridyl ether 148a, 50-60% of the product formed was the benzyl amine

150. The resulting benzyl group was attempted to be removed by hydrogenation over
palladium on carbon with catalytic amounts of hydrochloric acid. However, even
catalytic amounts of concentrated HCl resulted in the cleavage of the pyridyl ether to
furnish 151. The benzoyl protecting group of 148a was attempted to be removed with
hydrazine (NH2NH2) in ethanol.91 After two days at reflux, only one third of the starting
material 148a was converted into the desired product 152. In addition, it must be noted
that this method should not be employed for the chlorinated analog 149, as it will
substitute hydrazine for the chlorine atom adjacent to the nitrogen atom.
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The amides 147-149 were deprotected in a refluxing solution of 2 N KOH in a 3:1
mixture of methanol to water (Scheme 25).92 This afforded the deprotected amines 153-

155 in high yield without the formation of the benzylated product and without risk of
ether cleavage. The amines were converted into the oxalic acid salts 156-158 to be used
in subsequent biological testing (Scheme 25).
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Internitrogen Distance Calculations
Though the nicotinic acetylcholine receptor pharmacophore model is incomplete,
many structural features of ligands have been proposed to enhance binding at the
receptor. One such feature is an optimum internitrogen distance between the basic
nitrogen of a molecule and the nitrogen of a pyridine ring present within the structure.
The original model of Beers and Reich predicted an optimum internitrogen distance of
4.97 Å based on the structure of nicotine. The discovery of epibatidine contributed to the
proposal of a new internitrogen distance of 5.1 Å-5.5 Å. The series of pyridyl ethers 32-

43, which are less toxic than epibatidine, suggests that the internitrogen distance of a
ligand should be within 5.9-6.4 Å where the optimum distance is 6.1 Å.
The distance between the basic nitrogen of the 7-azabicyclo[2.2.1]heptane ring
and the pyridine nitrogen of 149 was determined to be 6.48 Å by the X-ray crystal
structure (Figure 8). It should be noted that the crystal packing structure may not
represent the ligand’s conformation in solution. Modeling calculations based on the
minimum energy conformation (Chem3D® drawing) of the deprotected 7azabicyclo[2.2.1]heptane ring 155 show an internitrogen distances 6.36 Å (Figure 9).
Rotation of the pyridine ring about the oxygen-sp2-hybridized carbon in 30º increments
offers internitrogen distances of 6.21-6.59 Å (∆ 0.38 Å). Based on the structural
similarity of 155 and 153 to ABT-594 (39), as well as similar internitrogen distances, we
predict this series to have potent binding affinities similar to ABT-594. The 2-pyridyl
derivative 154 was calculated to have an internitrogen distance of 4.90 Å based on the
lowest energy conformation (Figure 10). The range of internitrogen distances calculated
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by rotation of the pyridine ring encompasses 4.70-5.20 Å (∆ 0.38 Å). Though less than
the optimum internitrogen distance calculated for the pyridyl ethers, these values
correspond with those calculated for epibatidine and nicotine. We also predict high
binding affinity similar to epibatidine based on the structural similarities of 154 and
epibatidine. Chem-3D calculations of the lowest energy conformation of (S)-nicotine
compute an internitrogen distance of 4.6 Å compared to the literature value of 4.97 Å.
The Chem-3D computations of the newly synthesized pyridyl ether analogs may have an
error of up to 0.37 Å.

Figure 9. Lowest energy conformation of 155 based on Chem3D calculations. N7-N13
distance equals 6.36 Å.
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Figure 10. Lowest energy conformation of 154 based on Chem3D calculations. N7-N13
distance equals 4.90 Å.

Synthesis and Binding Affinity of Rigid Acetylcholine Analogs
Chemistry

The synthesis of the rigid acetylcholine analogs begins with the formation of 2tropanone (73). This system can easily be derived from (-)-cocaine (70) as outlined by
Zhang, Lomenzo, and Trudell (Scheme 26).74 The confiscation grade cocaine was heated
to reflux in 12 M hydrochloric acid to afford (-)-anhydroecgonine hydrochloride (71).
The acid was thoroughly dried at 100 ºC (oil bath) under vacuum overnight and
pulverized before use in the following step. A suspension of the carboxylic acid 71 was
treated with diphenylphosphoryl azide (DPPA) and catalytic amounts of
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dimethylaminopyridine (DMAP). The slurry was stirred over 48 h at room temperature
to afford the azide 72. The crude azide was converted directly into the ketone 73 via a
Curtius rearrangement performed in 1N hydrochloric acid. The pure ketone 73 was
obtained by Kugehlohr bulb-to-bulb distillation in 77% overall yield.
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The β-2-tropanol (74) could be made from 2-tropanone (73) in the absence of any
α-2-tropanol via a dissolving metal reduction of sodium metal in 3-pentanol (Scheme
27).73 During this reaction, both endo and exo isomers were formed, however the βtropinol (exo) isomer is thermodynamically preferred to the α-2-tropanol, and after 20
hours at elevated temperatures any α-tropinol (75) formed was converted to β-2-tropanol
(74). The 2-tropanone (73) was selectively converted into the α-2-tropanol (75) by
hydrogenation in methanol catalyzed by PtO2 (Scheme 27). Elevated pressures of 45 psi
were necessary for the reaction to proceed to completion. The platinum catalyst
coordinates to the basic nitrogen of the tropane ring, thereby delivering the hydrogen
from the exo face of the ring that results in the endo alcohol 75 in 95% yield. It should be
noted that both alcohols 74 and 75 can be purified by column chromatography.93
However, the basic tropanes have an affinity for ‘sticking’ to the acidic silica gel of the
column and would decompose if not eluted in a timely fashion. Solvent systems with
high polarity (88:10:2 CHCl3:MeOH:NH4OH) and flash chromatography were employed
in order to ensure optimum yield.
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Conversion of the β-2-tropinol (74) into its corresponding ester 76 was not
achieved in high yields by treatment of the alcohol with acetyl chloride, catalytic amounts
of dimethylaminopyridine (DMAP) and triethylamine (TEA). This conversion was
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accomplished by treatment of the β-alcohol 74 with freshly distilled acetic anhydride
(Ac2O) and freshly distilled pyridine at room temperature. High yields were achieved if
the chromatography solvent system contained NH4OH in order to neutralize the acidic
sites of the silica gel. The β-2-acetoxytropane (76) was converted into the oxalic acid
salts for biological testing.
The quaternary 2-acetoxy-8-methyl-8-azabicyclo[3.2.1]octane methlyiodide (77)
was synthesized by treating the starting material 76 with methyl iodide (CH3I) in
refluxing tetrahydrofuran. Upon completion of the methylation, the solvent was removed
under reduced pressure and the resultant white solid was triturated with hexanes to afford
the quaternary salt 77 in almost quantitative yields.72 The purity of the resulting salt 77
was suitable for biological testing.
Demethylation of the β-acetoxytropane to the corresponding secondary amines 78
required a two step process. The tropane ring is first reacted with 1-chloroethylchloroformate (ACE-Cl) to form the N-chloroformate intermediate. Subsequent heating
in MeOH furnished the amine in moderate yields. Purification was accomplished by
formation of the hydrochloride salt. Anhydrous HCl gas was bubbled through cold
diethyl ether and the solution was slowly dropped into a solution of the free base until a
precipitate formed. The salts were only obtained in crystalline form by slow crystal
growth in THF at –20 ºC over several days.94
The α-acetoxytropane 78-81 derivatives were synthesized in the same manner as
the β-acetoxytropanes (Scheme 28). α-2-Tropinol (76) was converted into its
corresponding ester, α-2-acetoxytropane (78), with acetic anhydride in the presence of
pyridine. The ester 78 was transformed into the oxalic acid salt derivative for subsequent
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biological testing. The α-2-acetoxy-8-methyl-8-azabicyclo[3.2.1]octane methlyiodide
(79) was synthesized in the same fashion as the β-derivative. The demethylated βacetxytropane 81 was also synthesized as outlined in Scheme 28 and converted into the
HCl salt for biological testing.

Biology
The acetoxytropanes 77, 78, 80, 81 were tested at the neuronal nicotinic
acetylcholine receptor for comparison of their relative binding affinity to epibatidine
(Table 2). The values reported are concentrations at which 50% of the radiolabeled
epibatidine was displaced from the receptor active site. Rat cortex membrane tissue was
used, as it contained a high concentration of the α4β2 receptor subtype. The compounds
exhibited no measurable affinity for the central nervous system nicotinic acetylcholine
receptor affinity up to the highest dose tested (50 µM). The acetoxytropanes 77, 78, 80,

81 were also tested in Torpedo electric organ preparation to determine if the compounds
displayed affinity for the 2αβγδ neuromuscular nicotinic acetylcholine receptor. No
measurable response was detected at concentrations up to 5 µM. This translates to a 1001,000 fold decrease in affinity relative to nicotine and 1,000-10,000 fold decrease in
affinity relative to epibatidine at these receptor subtypes. Since binding in the
subnanomolar range was desired these compounds were deemed inactive, and therefore
not representitive of the conformation of acetylcholine inside the active site of the
nicotinic receptor.
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Table 2. Nicotinic Ligand Binding at CNS nAChRs (3H-Epibatidine displacement)
4

77

78

80

81

Agent

(-)-Epibatidine

SD-I-94

SD-I-103

SD-I-70

SD-I-80

Rat Cortex
Membranes
(α4β2)
Torpedo Electric
Organ (α1β1δγ)

1.5 pM

> 50 µM

> 50 µM

> 50 µM

> 50 µM

0.006 µM

> 5 µM

> 5 µM

> 5 µM

> 5 µM

Since the acetoxytropane derivatives were not active at the neuronal nicotinic
acetylcholine receptor, they were tested at muscarinic acetylcholine receptors to
determine if they resembled the conformation of acetylcholine at this receptor subtype.
One source that contains a high concentration of muscarinic receptors of αxβy subtype is
the guinea pig ileum. The compounds were tested for their minimum effective
concentration, or the concentration necessary produce the response seen with
acetylcholine binding (Table 3). Table 3 shows that the necessary stimulating
concentrations for 76-81 as agonists are 100-1,000 times higher than those for
acetylcholine. This revealed that the compounds are likewise 100-1,000 times less potent
than acetylcholine in this paradigm.
Antagonist properties of 76-81 were also measured as relative to atropine, a
known muscarinic antagonist (Table 3). This activity was reported as the minimal
effective blocking dose against acetylcholine. The α-2-acetoxytropane 79, the α-2acetoxytropane methiodide 80, and the desmethyl α-2-acetoxytropane 81 are 200-fold
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less potent than atropine. The β-2-acetoxytropane 76 and the desmethyl β-2acetoxytropane were also 200-fold less potent and the β-2-acetoxytropane was 400-fold
less potent than atropine in this paradigm.

Table 3. Acetylcholine-like potency in isolated guinea pig ileum
Agent
SD-I-70 (79)

Agonist EC min (µg/mL)
(range) [N]*
>40 [2]

Antagonists EC50 against
ACh (range) [N]
15 [2]

SD-I-71 (80)

100 (30-240) [4]

30 [3]

SD-I-80 (81)

120

25 [2]

SD-I-94 (76)

400 (120-800) [7]

25 [3]

SD-I-103 (77)

80 (30-160) [7]

40 [3]

SD-I-109 (78)

10 (4-20) [6]

7 (5-20) [6]

ACh Cl

0.2 (0.05-0.4) [7]

-----

Atropine SO4

-----

0.02 (0.007-0.05) [7]

*EC min = minimal stimulant concentration, [N] = number of tests

A paradigm similar to the guinea pig ileum was investigated to study possible
agonist and antagonist activity at the muscarinic acetylcholine receptor in rat (Table 4).
Rat jejunum preparation displays concentration of a distinct muscarinic acetylcholine
receptor αxβyβz, different from the subtype present in guinea pig illeum. The series
proved to be inactive in this paradigm as well. The analogs 79, 80, and 81 were 200-300fold less potent than acetylcholine as an agonist and 80 and 81 were 500-1,000-fold less
potent as antagonists when compared to atropine.
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Table 4. Acetylcholine-like muscarinic potency in isolated rat jejunun

SD-I-70 (78)

Agonist EC min µg/mL
(range) [N]*
100 [4]

Antagonnist EC50 against
ACh (range) [N]
-----

SD-I-71 (80)

100 [3]

50 [2]

SD-I-80 (81)

150 [2]

20 [2]

ACh Cl

0.5 (0.2-1.0) [4]

-----

Atropine SO4

-----

0.05 [2]

Agent

*EC min = minimal stimulant concentration, [N] = number of tests

Advanced testing was performed on the β-acetoxytropanes 76 and 77. A live
animal model was used to study the acetylcholine derivatives’ effects on rat blood
pressure. Atropine blocks the acetylcholine response and causes a decrease in blood
pressure in animal models. Where 0.5-1 µg of atropine per 1 kg of rat is required to illicit
an acetylcholine blocking response, 500 µg or more was required of the rigid
acetylcholine derivatives 76 and 77 to achieve the same response. The β-2acetoxytropanes were 1000-fold less potent in this paradigm. Potency was also measured
at the ganglionic α7 nAChR subtype found in rat spinal cord by observing nicotinic
pressor response. Where nicotine produces an increase in blood pressure at
concentrations as low as 120 µg/mL, compounds 76 and 77 were completely inactive,
even at concentrations up to 2 mg/mL.
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Table 5. Rat blood pressure and spinal rat preparation tests on 76 and 77
Agent
SD-I-94 (76)

Minimal Ach Blocking
Dose in Rat Blood Pressure
Model
>500 µg/kg

Spinal Rat Preparation
Inactive up to 2 mg/mL

SD-I-103 (77)

500 µg/kg

Inactive up to 2 mg/mL

Atropine

0.5-1 µg/kg

---

Nicotine

---

120 g/mL

Though a search was performed to determine if acetylcholine adopts a
conformation similar to the one held in the rigid acetylcholine derivatives synthesized in
this study, no significant biological activity was observed. We can conclude that
acetylcholine adopts a conformation when bound to the active site of the nicotinic and
muscarinic receptor subtypes tested that does not resemble the conformation imparted by
the rigid tropane system. Alternatavely, the low binding affinity of the 2-acetoxytropanes
may be ascribed to the additional steric interactions at the nAChR introduced by the
tropane ring.
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Synthesis of Anabasamine and Related Alkaloids

The synthesis of (±)-anabasamine was designed to be a versatile synthetic route
with variability at each step to produce a number of different analogs and series of
compounds. The first step in the synthesis involved the lithiation of commercially
available 5-bromo-2-methoxypyridine (90). n-Butyllithium was added to a stirred
solution of the pyridine in diethyl ether at –78 ºC over 15 minutes.95 When the pyridyl
lithium reagent was generated, the diluted δ-valerolactone (89) was added over 15
minutes. Stirring for 2 hours at room temperature was suffucient to facilitate the ring
opening of the lactone and acylation of the pyridine ring. This afforded the keto-alcohol

88 in 94% yield. The concentration of the reaction proved to have an effect on the yield
of the keto-alcohol 88. Concentrations less than 0.04 M of 5-bromo-2-methoxypyridine
increased the yield by decreasing the possibility of a second pyridyl anion addition to the
ketone product 88. The pyridyl anion addition to the ketone resulted in the formation of
the biaryl diol 88b. Another factor that effected the yield was the purity of the
valerolactone. The reagent is only be available in technical grade and may contain up to
25% of an unreactive polymer. When the reagent was stored at –20 ºC, polymerization
was minimized and yields of 88 were generally increased.
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Employing alternate lactones furnished keto-alcohols of varied chain-length. The
butanol derivative 95 was generated in a similar manner to the pentanol 88 with the
addition of δ-butyrolactone to the pyridine anion of 90 (Scheme 29). This afforded 95 in
89% yield. Up to 20% of the side product 95b was isolated with higher concentrations of
the reagents. However, lower concentrations of the reagents resulted in a decreased
occurrence of the second addition product 95b. It is important to note that reaction times
increased for the less concentrated solution. The biaryl compound 95b was identified by
mass spectroscopy and by 2D COSY 1H NMR.
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A variety of different oxidation agents were employed to oxidize the primary
alcohol of 88 to afford the keto-aldehyde 87. Oxidation of the alcohol with chromium
regents (pyridinium dichromate and pyridinium chlorochromate) did not afford the
product in sufficient purity. Due to the instability of the aldehyde to purification by
column chromatography, an oxidation that proceeded with the formation of efficiently
removed by-products in the workup was required. The Dess-Martin reagent was
successful in oxidizing the primary alcohol 88 to afford the keto-aldehyde 87 in almost
quantitative yield with negligible impurities as detected by TLC and NMR (Scheme
30).96 The reaction was performed at room temperature in methylene chloride with 1.45
equivalents of the Dess-Martin reagent. The excess reagent allowed the reaction to be
completed in 1.5 h. During the work-up, excess oxidizing agent was quenched with
sodium thiosulfate in a saturated solution of NaHCO3. It was beneficial to vigorously stir
the reaction mixture and the aqueous mixture together for 10-20 minutes until the organic
layer was rendered colorless. This thoroughly extracted excess oxidizing agent, acetic
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acid, and other byproducts of the Dess-Martin reagent, from the organic solution. The
presence of acetic acid or oxidizing agent was formed to effect the yield of the following
step by reacting with the reducing reagent utilized in the reductive amination (Scheme
31). With the keto-aldehyde 87 in hand, the reductive amination was performed
employing methylamine hydrochloride and sodium cyanoborohydride in methanol to
yield the piperidine analog.97
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Scheme 32
At this point, chlorination at the 2-position of the pyridine ring of 86 was desired
for several reasons. First, it was of interest to study the binding affinity of the chlorinated
piperidine analog 85 at the nicotinic acetylcholine receptor in comparison to epibatidine.
Second, the chlorine moiety was desired in the subsequent coupling step to introduce the
second 3-pyridyl ring of anabasamine. Chlorination methods utilizing
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dimethylformamide (DMF) resulted in the formylation of the pyridine ring. Also, since
the chloroinated product 85 exhibited higher water solubility than ether solubility,
separation of DMF from the compound by ether extraction proved to be very difficult.
Also, refluxing the aryl ether 86 in POCl3 using standard reflux apparatus did not yield
the desired chlorination products. The chlorination was achieved by heating the aryl
ether 86 in phosphorous oxychloride in a sealed reactor tube at 115 ºC for 24 hours.
Larger scales required 48 hours. The chlorinated pyridine derivative 85 could then be
obtained if careful work-up conditions were employed.
The workup for this reaction proved to be very important and must be performed
with extreme care in order to obtain the desired product. Once the reaction was cooled,
most of the POCl3 was removed by rotary evaporation. This minimized the amount of
reagent to be neutralized. The viscous residue was then dissolved in a small amount of
dichloromethane. Because the compound exists as the salt at this point, the salt is not
readily soluble in organic solvents. However, attempting to dissolve the residue in even a
small amount of cold water resulted in an exothermic reaction with residual phosphorous
oxychloride that led to decomposition of the product 85. The residue must then be first
added dropwise to ice water to quench the POCl3. The resulting aqueous mixture was
then added dropwise to a saturated solution of ice-cold sodium carbonate and a pH 10 is
maintained. If the base was added to the salt, or the salt was added to the base prior to
dilution with water, even at cold temperatures, the reaction bubbled violently and
decomposition occured. The basic aqueous layer was thoroughly extracted with copious
amounts of dichloromethane to retrieve the compound from the water layer. Purification
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by column chromatography resulted in the desired chlorinated pyridine 85 in moderate to
good yields (49-77%).
With the chloropyridine 85 in hand, the Suzuki-Miyaura coupling was then
employed utilizing a palladium catalyst 159 developed by Viciu, et al for aromatic ring
coupling reaction (Scheme 33).98 Much research has been devoted to attempting
aromatic coupling reactions utilizing chlorine atoms instead of the more expensive and
more reactive bromine or other derivatives. This catalyst 159 proved successful for
sufficient coupling of a 2-pyridyl chloride to a pyridyl boronic acid. To carry out the
coupling, a reaction tube was charged with 3-pyridine boronic acid (160), the palladium
catalyst 159, and the sodium tert-butoxide in an argon glove box. To the heterogeneous
mixture, a solution of the aryl chloride 85 in dry dioxane was added. The reaction was
stirred vigorously at 80 ºC for 9 hours to afford the biaryl natural product, (±)anabasamine (84) in 55% yield.99 The limitation of this procedure is primarily the
insolubility of the pyridyl boronic acid in dioxane. Pyridine boronic acids exhibit even
lower solubilities than their benzene counterparts and more dilute reaction conditions
were required than desired. The rate of the reaction varies directly with concentration.
Though the reaction is run under dry conditions, water is not the greatest concern as
interference in the mechanism. However, the reaction must be performed under
anaerobic conditions to prevent deactivation of the palladium catalyst and to ensure high
conversion.
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The pyrrolidine analog of anabasamine 91 was synthesized in a similar fashion to
anabasamine (Scheme 34). Starting with 4-hydroxy-1-(6-methoxy-pyridin-3-yl)-butan1-one (95) the Dess-Martin oxidation and reductive amination were subsequently
employed as illustrated in Schemes 30 and 31. At this point, racemic 6-methoxy nicotine
(93) was made in three steps with an overall yield of 54%. This is a marked
improvement over the previous methods described in the literature of 16% overall yield
in 5 steps. The nicotine analog 93 had been used, and continues to be used as a common
drug intermediate for the development of a number of substituted nicotine analogs.
The methoxy moiety of 6-methoxynicotine (93) was substituted with a chlorine to
generate the aryl chloride 92 appropriate for the Sizuki-Myaura coupling reaction. With
the aryl chloride 92 in hand, the biaryl coupling was carried out with 3-pyridine boronic
acid as described in Scheme 33 to afford the nicotine analog 91 in 50% yield.
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CONCLUSION

In conclusion, three new classes of nicotinic acetylcholine receptor ligands have
been developed. The first series of analogs (147-149) consists of hybrid structures of
epibatidine (4) and ABT-594 (39). The 1-pyridyl ether-7-azabicyclo[2.2.1]heptane
derivatives 147-149 were synthesized in 14 steps in a 7-13% overall yield. Previous
studies have demonstrated that an optimum distance between the basic nitrogen and the
pyridyl nitrogen of many nAChR ligands, such as epibatidine and ABT-594, is crucial for
potent activity. The 1-pyridyl ether-7-azabicyclo[2.2.1]heptane derivatives are
structurally similar to ABT-594 with a 3-atom extension (C-C-O) between the basic
nitrogen of the heptane ring and the pyridyl ring. The most recent pharmacophore model
for the nicotinic receptor calculates an optimum internitrogen distance to be 6.1 Å based
on the structure of ABT-594 and other pyridyl ethers. Chem3D® calculations of the
internitrogen distances of 147 and 148 revealed lengths (6.2-6.6 Å) that correspond to the
optimum distance. The internitrogen distance of the 2-pyridyl ether 154 weas calculated
in the same fashion to reveal distances of 4.7-5.2 Å, similar to the 5.1 Å internitrogen
distance of epibatidine. The oxalic acid salts of the bicyclic pyridyl ethers are presently
being tested for binding affinity at the nicotinic acetylcholine receptor. This new class of
compounds will potentially aid in the ever-developing nicotinic receptor pharmacophore
model. The results of these studies will be reported elsewhere.
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A stereoselective synthesis was developed for a series of rigid acetylcholine
analogs, the second class of nAChR ligands. These 2-acetoxytropanes were synthesized
in five steps from (-)-cocaine via the isomeric alcohols, α-2-tropinol and β-2-tropinol.
The previous synthesis of the alcohols required a difficult isomer separation, which was
alleviated by the method reported herein. The 2-acetoytropanes were tested for binding
affinity to the central nervous system subtype of the nicotinic acetylcholine receptor. The
assay showed low potency at the receptor with high concentrations necessary to displace
the [3H]epibatidine. Subsequent tests were performed to study if the compounds
displayed high binding affinity for the muscarinic acetylcholine receptor. All compounds
tested displayed low potencies in this assay as well. This suggested that the flexible
endogenous neurotransmitter, acetylcholine, adopts a conformation other than the one
imparted by the rigid tropane ring when in the active site of the receptor. Alternatively,
the low binding of the acetoxytropanes could also be due to unfavorable steric bulk of the
ligand created by the tropane ring.
Finally, the first total synthesis of the plant alkaloid, anabasamine, was developed.
The synthetic sequence for (±)-anabasamine (84) is concise and consists of only five
steps with a 29% overall yield. The route is equally efficient for both large and small
scale preparations. Two intermediates of the sequence, 85 and 86, as well as
anabasamine, will be tested as novel nicotinic acetylcholine ligands. Using a similar
synthesis, the pyrrolidine analog 91 of anabasamine was synthesized. This novel hybrid
structure of nicotine and anabasamine will be tested for nicotinic acetylcholine receptor
binding affinity. 6-Methoxynicotine (93), an intermediate in this synthesis, is a common
drug intermediate from which batteries of compounds are made to study the nicotinic
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receptor. The synthetic procedure for the synthesis of the tricyclic nicotine analog 91
offers the intermediate, 6-methoxynicotine (93), in three steps in 54% overall yield. This
is a marked increase over the previously accepted synthesis which afforded 93 in five
steps in 16% overall yield.
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EXPERIMENTALS
General Information
All chemicals were purchased from Aldrich Chemical Co., Milwaukee, WI,
unless otherwise noted. Anhydrous THF, CH2Cl2, Et2O, CH3CN and MeOH were
purchased from Mallinkrodt Baker. Anhydrous DMF was purchased in a sure-seal bottle
from Aldrich Chemical Co. Toluene and benzene were dried by distillation over
Na/benzophenone. Chromatography refers to column chromatography on silica gel
(Sorbent Technologies Silica Gel, 60Å, 32 – 63 µm Standard Grade). Reported melting
points were recorded on a Hoover Mel-Temp apparatus and are uncorrected. NMR
spectra were recorded on a Varian-Gemini 400 MHz spectrometer or as noted on a
Varian-Gemini 300 MHz or 500 MHz multiprobe spectrometer. Chemical shifts are
reported as δ values with deuterated chloroform (CDCl3) and tetramethylsilane (TMS)
(Cambridge Isotope Laboratories) employed as the internal standard. Elemental analyses
were obtained from Atlantic Microlabs, Inc., Norcross, GA. Mass spectra (LRMS) were
recorded on a Hewlett-Packard 5855 GC-MS (University of New Orleans).

8-Methyl-8-azabicyclo[3.2.1]octan-2-ol (75): 2-Tropinone (4.4g, 32 mmol) was
hydrogenated over PtO2 (150 mg) in MeOH (67 mL) at a constant pressure of 45 psi for 4
h. The solution was filtered and the residue was purified flash chromatography (SiO2,
CHCl3, MeOH, NH4OH 89:10:1) to yield 75 as a white solid (4.4 g, 99% yield) mp 76-77
ºC. 1H NMR (400 MHz, CDCl3) δ 2.04-1.96 (m, 1H), 1.87-1.80 (m, 1H), 1.76-1.49 (m,
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2H), 1.47-1.38 (m, 2H), 1.30-1.21 (m, 1H).

13

C NMR: (400 MHz, CDCl3) δ 69.0, 67.5,

60.7, 41.0, 30.1, 25.3, 25.0, 20.6.

Acetic acid 8-methyl-8-aza-bicyclo[3.2.1]oct-2-yl ester (79): To a stirred solution of α2-tropinol 75 (1.0 g, 7.1 mmol) in dry CH2Cl2 (10 mL) under an atmosphere of nitrogen
was added dry pyridine (1.90 mL) and freshly distilled acetic anhydride (1.9 mL). This
was stirred overnight at room temperature. The organic mixture was washed with a
solution of saturated NaHCO3 (11 mL). The aqueous layer was extracted with additional
CHCl3 (2 × 20 mL). The organic fractions were combined and the solvent removed
under reduced pressure. The oil was purified by column chromatography (SiO2, CHCl3:
MeOH: NH4OH, 90:9:1) to yield 79 as a colorless oil (1.1 g, 81% yield).

1

H NMR (400

MHz, CDCl3) δ 4.86 (q, J = 5.6 Hz, 1H), 3.17-3.14 (m, 1H), 3.08-3.06 (m, 1H), 2.29 (s,
3H), 1.86-1.73 (m, 4H), 1.48-1.35 (m, 4H).

13

C NMR (400 MHz, CDCl3) δ 169.7, 72.1,

63.6, 60.4, 40.3, 29.8, 25.0, 21.9, 21.5, 20.9.

Acetic acid 8-methyl-8-aza-bicyclo[3.2.1]oct-2-yl ester · oxalic acid: A solution of
acetoxy tropane (81 mg, 0.44 mmol) in a minimum amount of propanol was added to a
warm solution of oxalic acid (47 mg, 0.53 mmol, 1.2 eq) in propanol. THF was added
dropwise to crystallize the salt as a white solid mp 100-102 °C, [α]D 25 = +6.7 (c=1,
EtOH) Anal. Calcd. for C12H17O2N•C2O4H•0.75 H2O: C, 50.25; H, 7.20; N, 4.88.
Found: C, 50.44; H, 7.01; N, 4.83.

2-Acetoxy-8-methyl-8-azabicyclo[3.2.1]octane · methyliodide (80): To a stirred
solution of 79 (67 mg, 0.37 mmol) in freshly distilled THF (10 mL) under an atmosphere
of nitrogen was added CH3I (0.34 mL, 0.55 mmol) dropwise. The solution was heated to
reflux for 2 h. The solvent was removed under reduced pressure and the resulting fine
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powder was triturated with warm ether and then warm acetone to yield 80 as a white
powder (73 mg, 74%). mp 274°C. [α]D 25= +9.3 (c=1, EtOH). 1H NMR (400 MHz, D2O)
δ 4.41-5.43 (q, J = 1.6 Hz, 1H), 3.94-3.90 (m, 2H), 3.28 (s, 3H), 3.14 (s, 3H), 2.53-2.24
(m, 4H), 2.11 (s, 3H), 2.06-2.10 (m, 2H), 1.69-1.85, (m, 2H)

13

C NMR (400 MHz, d-

DMSO) 175.0, 74.0, 69.2, 68.5, 66.4, 52.8, 45.0, 26.25, 25.8, 21.8, 20.2. Anal. Calcd. for
C11H20NO2: C, 40.63; H, 6.20; N, 4.31. Found: C, 40.81; H, 6.22; N, 4.13.

2-Acetoxy-8-azonia-bicyclo[3.2.1]octane · HCl (81): To a stirred solution of the ester
6 (0.75g, 4.1 mmol) and K2CO3 (0.57g, 4.1 mmol) in dry toluene (35 mL) sealed under
an atmosphere of nitrogen was added 1-chloroethyl chloroformate (1.4 mL). The
solution was heated to reflux overnight. The solution was diluted with toluene, washed
with 1N HCl and then with brine. The organic layers were dried over Na2SO4,
concentrated and passed through a short column, first with CH2Cl2, then with EtOAc.
These fractions were concentrated to give a pale yellow oil. The oil was dried and
dissolved in MeOH, sealed under N2 and stirred at 25°C overnight. The crude pale
yellow oil was converted into the HCl salt by bubbling HCl (g) into dry diethyl ether at 0
ºC and slowly dropping the HCl-ether into a solution of the free amine in ether. The
resulting HCl salt was triterated 3 times with ether to give a pure white powder (460 mg ,
66% yield). Mp 242-244 °C (decomposed) [αD] 25 = +31.3, (c=1, EtOH). 1H NMR (400
MHz, D2O) δ 5.04 (m, 1H), 4.08 (m, 2H), 2.11 (s, 3H), 2.37-1.71 (m, 10 H).
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C NMR

(400 MHz, d-DMSO) δ 169.4, 67.7, 55.2, 53.7, 25.9, 25.4, 21.7, 21.5, 20.8. Anal. Calcd.
for C9H15NO2•HCl: C, 52.56; H, 7.84; N, 6.81. Found: C, 52.29; H, 7.70; N, 6.72.

8-Methyl-8-aza-bicyclo[3.2.1]octan-2-ol (74): To a solution of 2-tropinone 73 (5.0g, 36
mmol) in dry toluene (10 mL) under an atmosphere of nitrogen was added 3-pentanol (23
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mL, 0.22 mol). The resulting mixture was added to sodium powder (0.25 g, 0.11 mol) in
dry THF (20 mL) under nitrogen and over 45 minutes. This was heated to reflux
overnight. The organic layer was washed with deionized H2O (94 mL). The aqueous
layer was extracted with CH2Cl2 (4 × 100 mL). The combined organic layers were dried
over Na2SO4 and condensed. Purification by gravity column (SiO2: CHCl3: MeOH:
NH4OH 90:9:1) afforded 74 (3.3 g, 66% yield). 1H NMR (400 MHz, CDCl3) δ 3.75 (br s,
1H), 3.51 (m, 1H), 3.04 (m, 2H), 2.20 (s, 3H), 2.01-1.56 (m, 3H), 1.56-1.41 (m, 4H),
1.30-1.26 (m, 1H).

Acetic acid 8-methyl-8-aza-bicyclo[3.2.1]oct-2-yl ester (79): To a stirred solution of β2-tropinol 74 (1.9g, 14 mmol) in dry CHCl3 (19 mL) under an atmosphere of nitrogen
was added dry pyridine (4 mL, 46 mmol) and dry acetic anhydride (3.7 mL, 39 mmol).
The solution was stirred at room temperature overnight. The reaction was quenched with
a saturated solution of NaHCO3 (22 mL) and the organic layer was removed. The
aqueous layer was washed with CHCl3 (3 × 45 mL) and the organic fractions were
combined and concentrated. Purification was achieved by flash chromatography (SiO2,
CHCl3 : MeOH, 90:10) to yield 79 as a colorless oil (0.83 g, 61% yield). 1H NMR (400
MHz, CDCl3) δ 4.66 (br s, 1H), 3.22 (br s, 1H), 3.19 (br s, 1H), 2.25 (s, 3H), 2.12 (s, 3H),
2.06-1.53 (m, 10 H).
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C NMR (400 MHz, CDCl3) δ 170.6, 72.0, 64.1, 61.0, 41.1, 28.5,

23.7, 23.1, 21.2, 20.7.

Acetic acid 8-methyl-8-aza-bicyclo[3.2.1]oct-2-yl ester · oxalate: The acetoxy tropane
79 (100 mg, 0.55 mmol) was dissolved in a minimum amount of propanol and added to a
warm solution of oxalic acid (59 mg, 0.65 mmol, 1.2 eq) in propanol. THF was added
dropwise to prompt the salt to crystallize as a white solid, mp 90-92°C, [α]D 25 = -9.2,
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(c=1, EtOH). Anal. Calcd. for C10H17NO2•C2O4H•1/2 H2O: C, 51.06 H, 7.14; N, 4.96.
Found: C, 51.12; H, 6.95; N, 4.96.

2-Acetoxy-8-methyl-8-azabicyclo[3.2.1]octane · methyliodide (77): To a stirred
solution of the ester 10 (.270 g, 1.4 mmol) in dry THF (35 mL) under an atmosphere of
nitrogen was added CH3I (1.27 mL). The reaction was heated to reflux overnight to give

77 as a white solid (64 mg, 24% yield). mp 276-278°C [αD]25= -6.2, (c=1, EtOH). 1H
NMR (400 MHz, CDCl3) δ 5-44-5.42 (m, 1H), 3.91-3.95 (m, 2H), 3.28 (s, 3H), 3.14 (s,
3H), 2.29-2.22 (m, 4H) 2.11 (s, 3H0, 2.11-2.05 (m, 2H), 1.87-1.69 (m, 2H).
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C NMR

(400 MHz, CDCl3) δ 173.5, 76.4, 67.3, 52.4, 44.6, 30.5, 25.7, 25.3, 21.4, 21.3, 19.6.
Anal. Calcd. for C11H20NO2: C, 40.63; H, 6.20; N, 4.31. Found: C, 40.86; H, 6.23; N,
4.30.

2-Acetoxy-8-azabicyclo[3.2.1]octane · HCl (78): To a stirred solution of the ester 76
(1.0 g, 6.1 mmol) and K2CO3 (840 mg, 6.1 mmol) in dry toluene (50 mL) under an
atmosphere of nitrogen was added 1-chloroethyl chloroformate (ACE-Cl) (1.8 mL, 12
mmol). The reaction was heated to reflux for 30 h and then two more equivalents of
ACE-Cl (1.8 mL, 12 mmol) were added. The reaction mixture was refluxed for an
additional 18 h. The solution was filtered and the filtrate rinsed with CH2Cl2. The
toluene was removed under reduced pressure and dried over Na2SO4. The resulting
brown oil was stirred under nitrogen in dry MeOH (40 mL) at 25 °C for 24 h. The
solvent was removed under reduced pressure. The resulting residue was converted to the
HCl salt by bubbling HCl (g) into dry diethyl ether at 0 ºC and slowly dropping the HClether into a solution of the free amine in ether. The salt was recrystallized from MeOH
and THF at –20 ºC over 4 days. The resulting HCl salt was triturated 3 times with ether
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to give a pure white crystalline solid. mp 228-230 ºC (dec.) [α]D 25= -18.6, (c=1, EtOH).
1

H NMR (400 MHz, MeOD) δ 6.48 (br s, NH) 4.88 (m, 1H), 4.15 (s, 1H), 4.08 (s, 1H)

2.36 (m, 2 H), 2.24 (s, 3H), 1.95-1.75 (m, 4H), 1.67 (m, 2H).
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C NMR (400 MHz,

CDCl3) δ 170.2, 68.42, 56.5, 54.1, 24.8, 24.0, 23.5, 21.0, 20.2. Anal. Calcd. for
C9H15NO2•HCl: C, 52.56; H, 7.84; N, 6.81. Found: C, 52.50; H, 7.90; N, 6.79.

5-Hydroxy-1-(6-methoxy-pyridin-3-yl)-pentan-1-one (88): To a stirred solution of 5bromo-2-methoxypyridine (2.50, 1.72 mL) in dry Et2O (50 mL) was added a solution of
n-BuLi in hexanes (9.14 mL, 1.6 M) dropwise over 15 minutes at –78ºC. The solution
was stirred for an additional 15 minutes at –78 ºC and then a solution of δ-valerloactone
(1.23 mL, 13 mmol) in Et2O was added dropwise. The reaction was stirred at room
temperature for 2 h. Brine (25 mL) was added to quench the reaction and the organic
layer was removed. The aqueous layer was extracted with EtOAc (2 × 50 mL) and
CHCl3 (2 × 50 mL) and condensed under reduced pressure. The residue was purified by
flash column chromatography (SiO2: EtOAc) to afford a pale yellow solid (2.5 g, 89 %),
yield mp 34-36 ºC. 1H NMR (400 MHz, CDCl3) δ 8.80 (d, J = 2.4 Hz, 1H), 8.15 (dd J1 =
8.8 Hz, J2 = 2.4, 1H), 6.80 (d, J = 8.4 Hz, 1H), 4.01 (s, 3H), 3.68 (m, 2H), 2.98 (t, J = 6.8
Hz, 2H), 1.85 (q, J = 7.2 Hz, 2H), 1.66 (m, 2H). 13C NMR (400 MHz, CDCl3) δ 198.4,
166.8, 149.1, 138.3, 126.7, 111.2, 62.3, 54.2, 38.1, 32.2, 20.4. Anal. Calc. for C11H15NO3
C, 63.14; H, 7.23; N, 6.69. Found: C, 63.32; H, 7.33; N, 6.68.

5-(6-Methoxy-pyridin-3-yl)-5-oxo-pentanal (87): To a stirred solution of the alcohol
88 (0.61 g, 2.9 mmol) in CH2Cl2 (60 mL) under an atmosphere of nitrogen was added a
25% weight solution of prepared Dess-Martin reagent in CH2Cl2 (8.8 mL, 4.3 mmol).
The reaction was stirred at room temperature for 1.5 h. The reaction was then diluted
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with Et2O and poured into a solution of Na2S2O3 in saturated NaHCO3 (60 mL) and
stirred for 5 min until clear. A pH 7 buffer was added and the mixture was extracted with
Et2O (3 × 50 mL). The organic layer was washed an additional time with saturated
NaHCO3 (60 mL) and H2O (60 mL). The organic fractions were combined and dried
over Na2SO4. The solvent was removed under reduced pressure to afford the crude
aldehyde in almost quantitative yield. The aldehyde was used in the following step
without further purification. 1H NMR (400 MHz, CDCl3) δ 9.81 (s, 1H), 8. 79 (d, J = 1.6
Hz, 1H), 8.13 (dd, J1 = 8.8 Hz, J2 = 2.8, 2H) 6.79 (d, J = 8.8 Hz, 1H), 4.01 (s, 3H), 3.00
(t, J = 6.8 Hz, 2H), 2.61 (t, J = 6.8, 2H), 2.07 (q, J = 7.6 Hz, 2H).
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C NMR (400 MHz,

CDCl3) δ 201.8, 197.0, 166.7, 148.9, 138.0, 111.1, 54.0, 43.0, 37.1, 16.4.

6'-Methoxy-1-methyl-1,2,3,4,5,6-hexahydro-[2,3']bipyridinyl (86): The aldehyde
(3.70 g, 17.9 mmol), NH2CH3· HCl (1.21 g, 17.9 mmol) and NaBH3CN (1.68 g, 26.8
mmol) were dissolved in dry MeOH (100 mL) under an atmosphere of nitrogen. The
reaction was stirred for 48 h at room temperature. The MeOH was removed under
reduced pressure and saturated Na2CO3 (aq) was added to the residue. The aqueous layer
was extracted CHCl3 (3 × 100 mL). The residue was purified by gravity column
chromatography (SiO2, MeOH:CH2Cl2 1:9) to afford the product as a yellow oil (2.0 g,
53% yield). 1H NMR (400 MHz, CDCl3): δ 8.02 (d, J = 2 Hz, 1H), 7.61 (dd, 1 = 8.6 Hz
J2 = 2.4, 1H), 6.71 (d, J = 8.4 Hz, 1H), 3.93 (s, 3H), 3.02 (d, J = 11.6 Hz, 1H), 2.75 (dd,
J1 = 11 Hz, J2 = 2.4, 1H), 2.14-2.06 (m, 1H), 1.99 (s, N-CH3), 1.81 (d, J = 12.8, 1H),
1.73-1.52 (m, 4H), 1.42-1.30 (m, 1H). 13C NMR (400 MHz, CDCl3) δ 163.6, 145.8,
137.7, 111.0, 67.5, 57.5, 53.4, 44.4, 35.7, 26.0, 24.9. Anal. Calc. for C12H18N2O: C,
69.87; H, 8.80; N, 13.58.
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6'-Chloro-1-methyl-1,2,3,4,5,6-hexahydro-[2,3']bipyridinyl (85): (80 mg, 0.42 mmol)
The aryl ether 86 was dissolved in POCl3 (3 mL) and sealed in a high pressure reactor
tube. The reaction was stirred at 115 ºC for 24 h. The excess POCl3 was removed of
under reduced pressure. The viscous residue was slowly added dropwise into ice water.
The aqueous solution was slowly added to ice cold saturated Na2CO3 at pH=10. The
aqueous phase was extracted with CH2Cl2 (5 × 25 mL), dried with Na2SO4, and
condensed under reduced pressure. The residue was purified by gravity column
chromatography (SiO2, MeOH:CH2Cl2 1:9) to afford the product as a brown oil (55 mg,
77% yield based on recovered starting material). 1H NMR (400 MHz, CDCl3): δ 8.29 (d,
J = 2 Hz, 1H), 7.67 (dd, J1 = 7.6 Hz J2 = 2.4, 1H), 7.29 (d, J = 8.4 Hz, 1H), 3.02 (d, J =
11.6 Hz, 1H), 2.82 (dd, J1 = 12 Hz, J2 = 3.2, 1H), 2.14-2.08 (m, 1H), 1.98 (s, N-CH3),
1.82 (d, J = 12, 1H), 1.73-1.66 (m, 4H), 1.55-1.33 (m, 2H). 13C NMR (400 MHz, CDCl3)
δ 150.1, 149.1, 139.5, 137.9, 124.4, 65.5, 57.3, 44.6, 36.2, 26.0, 24.8.

(+)-Anabasamine (84): A reaction tube was charged with the N,N’-bis(2,6diisopropylphenyl)-4,5-dihydroimidazol-2-ylidine (20 mg, 0.35 mmol), pyridine-3boronic acid (64 mg, 0.53 mmol), and sodium tert-butoxide (67 mg, 0.69 mmol) in an
atmosphere of argon. A solution of the 2-chloropyridine 85 (73 mg, 35 mmol) in dry
dioxane (5 mL) was added to the heterogenous mixture. The reaction mixture was stirred
vigorously in an 85 ºC oil bath for 8 h. The reaction was cooled and the catalyst filtered
through a short column (SiO2, MeOH:CH2Cl2 1:9) to furnish the natural product 84 as a
brown oil (48 mg, 75% yield based on recovered starting material). 1H NMR (400 MHz,
CDCl3): δ 9.20 (d, J = 1.6, 1H), 8.65 (d, J = 1.6, 1H), 8.63 (s, 1H), 8.33 (dd, J = 8, J =
1.2, 1H), 7.81 (dd, J = 8, J = 2, 1H), 7.73 (d, J = 8, 1H), 7.40 (m, 1H), 3.06 (d, J = 11.6,
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1H), 2.89 (dd, J = 11.2, J = 2.4, 1H), 2.18-2.12 (m, 1H), 2.04 (s, 3H), 1.86-1.54 (m, 6H)
13

C NMR (400 MHz, CDCl3) δ 153.9, 149.9, 149.8, 148.3, 139.8, 136.1, 135.0, 134.4,

123.8, 120.7, 68.1, 57.5, 44.8, 36.1, 26.1, 24.9.

4-Hydroxy-1-(6-methoxy-pyridin-3-yl)-butan-1-one (95): To a stirred solution of 5bromo-2-methoxypyridine (5.0 g, 26 mmol) in dry Et2O (100 mL) was added a solution
of n-BuLi in hexanes (18.2 mL, 1.6 M) dropwise over 15 minutes at –78ºC. The solution
was stirred for an additional 15 minutes at –78 ºC and then a solution of γ-butyroloactone
(1.91 mL, 26.6 mmol) in Et2O was added dropwise. The reaction was stirred at room
temperature for 2 h. Brine was added to quench the reaction and the organic layer was
removed. The aqueous layer was extracted with EtOAc (2 × 50 mL) and CHCl3 (2 × 50
mL) and condensed. The residue was purified by column chromatography (SiO2:
CHCl3:MeOH 95:5) to afford a pale yellow solid (2.5 g, 55 % yield), mp 32-34 ºC, and
the bipyridyl by-product 95b (20%). 1H NMR (400 MHz, CDCl3) δ 8.82 (d, J = 2, 4 Hz,
1H), 8.15 (dd, J1 = 8 Hz, J2 = 2.4 Hz, 1H) 6.79 (d, J = 8.8 Hz, 1H), 3.75 (m, 2H), 3.08 (t,
J = 7.6 Hz, 2H) 2.02 (q, J = 6.4, 2H), 1.85 (OH).
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C NMR (400 MHz, CDCl3) δ 198.3,

166.8, 149.1, 138.2, 126.6, 111.2, 62.1, 54.1, 35.1, 26.8. Mass Spec (ES) m/z 196.1
(M+). Anal. Calc. for C10H12NO2Cl·1/8 H2O C, 160.82; H, 6.70; N, 7.09. Found: C,
60.88; H, 6.72; N, 7.09.

5-(6-Methoxy-pyridin-3-yl)-4-oxo-butanal (94): To a stirred solution of the alcohol
95(0.44 g, 2.3 mmol) in CH2Cl2 (60 mL) under an atmosphere of nitrogen was added a
25% weight solution of prepared Dess-Martin reagent in CH2Cl2 (5.8 mL, 2.6 mmol).
The reaction was stirred at room temperature for 1.5 h. The reaction was then diluted
with Et2O and poured into a solution of Na2S2O3 in saturated NaHCO3 (60 mL) and
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stirred for 5 min until clear. A pH 7 buffer was added and the mixture was extracted with
Et2O (3 × 50 mL). The organic layer was washed an additional time with saturated
NaHCO3 and H2O. The organic fractions were combined and dried over Na2SO4. The
solvent was removed under reduced pressure to afford the crude aldehyde 94 (0.42 g) in
almost quantitative yield. The aldehyde was used in the following step without further
purification. 1H NMR (400 MHz, CDCl3) δ 9.90 (s, 1H), 8. 34 (s 1H), 8.15 (dd, J1 = 8.8
Hz, J2 = 2.0, 1H) 6.79 (d, J = 8.8 Hz, 1H), 3.27 (t, J = 6.0 Hz, 2H), 2.94 (t, J = 6.4, 2H).

2-Methoxy-5-(1-methyl-pyrrolidin-2-yl)-pyridine (93): The aldehyde 94 (1.52 g, 7.81
mmol), NH2CH3· HCl (0.527 g, 7.81 mmol) and NaBH3CN (0.736 g, 11.7 mmol) were
dissolved in dry MeOH (100 mL) under an atmosphere of nitrogen. This was stirred for
48 h at room temperature. The MeOH was removed under reduced pressure and
saturated Na2CO3 (aq) was added to the residue. The aqueous layer was extracted with
CHCl3 (3 × 100 mL). The residue was purified by gravity column chromatography (SiO2,
MeOH:CH2Cl2 1:9) to afford 93 as a yellow oil (800 mg, 53% yield). 1H NMR (400
MHz, CDCl3): δ 8.03 (d, J = 2.4 Hz, 1H), 7.62 (dd, 1 = 8.6 Hz J2 = 2.4, 1H), 6.74 (d, J =
8.8 Hz, 1H), 3.93 (s, 3H), 3.24 (t, J = 8 Hz, 1H), 3.01 (t,,J2 = 8.4, 1H), 2.28 (q, J = 8.8
Hz, 1H) 2.15 (s, 3H), 2.01-1.68 (m, 5H),
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C NMR (400 MHz, CDCl3) δ 163.8, 146.1,

137.8, 131.0, 111.1, 68.4, 57.0, 53.4, 40.2, 34.7, 22.4. Anal. Calc. for C12H18N2O: C,
69.87; H, 8.80; N, 13.58.

2-Chloro-5-(1-methyl-pyrrolidin-2-yl)-pyridine (92): The 2-methoxypyridine 93 (80
mg, 0.39 mmol) was dissolved in POCl3 (3 mL) and sealed in a high pressure reactor
tube. The reaction was stirred at 115 ºC for 24 h. The excess POCl3 was then removed
under reduced pressure. The viscous residue was slowly dropped into ice water. The
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aqueous solution was added dropwise to cold Na2CO3 the pH=10. The aqueous phase
was extracted with CH2Cl2 (5 × 25 mL), dried over Na2SO4, and condensed under
reduced pressure. The residue was purified by gravity column chromatography (SiO2,
MeOH:CH2Cl2 1:9) to afford the product as a brown oil (45 mg, 55% based on recovered
starting material). 1H NMR (400 MHz, CDCl3): δ 8.30 (d, J = 2 Hz, 1H), 7.68 (dd, J1 =
8.4 Hz J2 = 5.2, 1H), 7.29 (d, J = 8.4 Hz, 1H), 3.23 (m, 1H), 3.09 (t, J = 8 Hz), 2.31 (m,
2H), 2.16 (s, N-CH3), 2.01-1.91 (m, 1H), 1.90-1.78 (m, 1H), 1.72-1.64 (m, 1H). 13C NMR
(400 MHz, CDCl3) δ 150.2, 149.3, 138.0, 137.5, 124.4, 68.2, 57.1, 40.5, 35.5, 22.7

5-(1-Methyl-pyrrolidin-2-yl)-[2,3']bipyridinyl (91): A reaction tube was charged with
the N,N’-bis(2,6-diisopropylphenyl)-4,5-dihydroimidazol-2-ylidine (45 mg, 0.23 mmol),
pyridine-3-boronic acid (42 mg, 0.34 mmol), and sodium tert-butoxide (44 mg, 0.46
mmol) in an atmosphere of argon. A solution of the 2-chloropyridine 92 (45 mg, 0.23
mmol) in dry dioxane (4 mL) and added to the heterogenous mixture. The reaction
mixture was stirred vigorously in an 85 ºC oil bath for 8 h. The reaction was cooled and
the catalyst filtered through a short column (SiO2, MeOH:CH2Cl2 1:9) to furnish the
natural product as a brown oil (11 mg, 64% based on recovered starting material).m/z =
240 (M + 1). 1H NMR (400 MHz, CDCl3): δ 9.19 (s, 1H), 8.64 (s, 2H), 8.32 (d, J =
8.4,1H), 7.84 (dd, J = 8, J = 1.6, 1H), 7.74 (d, J = 8.4, 1H), 7.41 (q, J = 4.1, 1H), 3.29 (t,
J = 8, 1H), 3.18 (t, J = 8.4, 1H), 2.39-2.33 (m, 2H), 2.22 (s, 3H), 2.07-1.74 (m, 4H)
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C

NMR (400 MHz, CDCl3) δ 150.1, 150.0, 148.4, 136.2, 135.5, 134.5, 123.8, 120.8, 68.8,
57.2, 40.6, 35.4, 22.8.

1-Acetylamino-4-oxo-cyclohex-2-enecarboxylic acid methyl ester (100). To a stirred
solution of Danishefsky’s Diene (20 g, 0.12 mol) in dry toluene (360 mL) under an
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atmosphere of nitrogen was added a solution of methyl-2-acetamidoacrylate (4.2 g, 0.03
mol) dissolved in toluene (30 mL). The solution was heated to reflux for 24 h and then
an additional equivalent of the dienophile (4.2 g, 0.03 mol) in of toluene (30 mL) was
added. The reaction mixture was then heated to reflux for an additional 68 h. The
toluene was removed under reduced pressure and the resulting brown residue was
dissolved in a 1:4 mixture of 0.005 M HCl :THF (60 mL: 240 mL). The solution was
then stirred at room temperature for 15 h. After the hydrolysis of the trimethylsilyl group
was completed by TLC, the THF was removed under reduced pressure. The crude
material was dissolved in CH2Cl2 (160 mL), washed with brine (2 × 160 mL) and
saturated NaHCO3. The aqueous layers were additionally extracted with CH2Cl2 (2 × 160
mL) and EtOAc (2 × 160 mL). The organic fractions were combined and dried over
Na2SO4 and condensed to an amber oil. This was brought to the next step without
purification. To a stirred solution of the crude residue dry CH2Cl2 (320 mL) under an
atmosphere of nitrogen was added DBU (1,8-diazabicyclo[5.4.0]undec-7-ene) (4.2 mL)
dropwise at 0 ºC and stirred at this temperatue for 24 h. When all of the starting material
was consumed (TLC), the organic layer was washed with 0.5 M HCl (200 mL) and the
aqueous layer was extracted with CH2Cl2 (5 × 50 mL). The organic fractions were
combined, dried over Na2SO4, and concentrated under reduced pressure. The brown oil
was purified by column chromatography (SiO2, CHCl3:MeOH, 9:1) to afford 100 (9.2 g,
75% yield) as an amber oil. 1H NMR (CDCl3) δ 7.05 (d, J = 12 Hz, 1H), 6.47 (br s, NH),
6.11 (d, J= 12 Hz, 1H), 3.74 (s, 3H), 2.59-2.40 (m, 4H), 1.98 (s, 3H).
197.4, 171.2, 170.2, 147.1, 129.9, 57.8, 53.1, 33.5, 31.4, 22.7.
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C NMR (CDCl3):
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1-Acetylamino-4-oxo-cyclohexanecarboxylic acid methyl ester (101): The enone 100
(9.2 g) was hydrogenated at 1 atm over 10% Pd/ carbon (1.3 g) in CH2Cl2 (250 mL) for
36 h. The solution was filtered through a pad of Celite. The solvent was removed under
reduced pressure and the resulting residue was recrystallized from hexane:EtOAc (1:9) to
yield 101 as a white solid (7.7 g, 82% yield). 1H NMR (CDCl3): δ 6.66 (br s, NH), 3.75
(s, 3H), 2.49-2.46 (m, 4H), 2.38-2.35 (m, 4H), 2.05 (s, 3H).
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C NMR (CDCl3): δ 209.7,

173.3, 171.2, 57.4, 52.4, 36.4, 31.9 (2), 22.7 (2).

Trans-1-Acetylamino-4-hydroxy-cyclohexanecarboxylic acid methyl ester (102): To
a stirred solution of the ketone (1.9 g, 8.9 mmol) in dry THF (140 mL) under an
atmosphere of nitrogen at –78 ºC was added a solution of L-Selectride (14 mL, 1 M) over
25 minutes. The reaction was stirred at this temperature for 3 h. Saturated NH4Cl (60
mL) was added and the mixture was allowed to come to room temperature. The
solutiuon was filtered and condensed under reduced pressure at room temperaure. The
aqueous mixture was extracted with CH2Cl2 (5 × 50 mL) and the organic fractions
combined, dried (Na2SO4) condensed to afford a yellow residue. This was
chromatographed (SiO2 CHCl3: MeOH 9:1) to give the mixture of alcohols (cis:trans 1:9)
as a white solid (1.6 g, 81% yield). Data for 102: 1H NMR (CDCl3): δ 5.69 (br s, NH),
3.92 (br s, OH), 3.73 (s, 3H), 2.33 (m, 1H), 2.01 (s, 3H), 1.84-1.67 (m, 8H).
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C NMR

(CDCl3): δ 175.8, 169.9, 75.5, 55.1, 26.4 (2), 25.8 (2), 24.2.
N-(3-Oxo-2-oxa-bicyclo[2.2.2]oct-4-yl)-acetamide (104): To a stirred solution of the
ketone (1.9 g, 8.9 mmol) in dry THF (140 mL) under an atmosphere of nitrogen at –78 ºC
was added a solution of L-Selectride (14 mL, 1 M) over 25 minutes. The reaction was
stirred at this temperature for 3 h. Saturated NH4Cl (60 mL) was added and the mixture
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was allowed to come to room temperature. The solutiuon was filtered and condensed
under reduced pressure at 65 ºC. The residue was washed with CH2Cl2 (5 × 50 mL) and
the organic fractions combined, dried (Na2SO4) condensed to afford a yellow residue.
This was purified by chromatography (SiO2 CHCl3: MeOH 9:1) to give the bicyclic
lactone 104 as a white solid (2.1 g, 95% yield). MS (CI) m/z 184 (M+, 1), 142. 1H NMR
(CDCl3): δ 6.76 (br s, NH), 4.75 (t, J = 4.4, 1H), 3.12 (td, J1-2 = 12.2 Hz, J2-3 = 5.2 Hz,
2H), 2.15-2.04 (m, 2H), 2.00 (s, 3H), 1.90 (t, J = 12.4 2H), 1.67 (t, J = 13, 2H).
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C

NMR (CDCl3): δ 175.5, 169.8, 75.2, 54.9, 26.3 (2), 25.6 (2), 24.0.

1-Acetylamino-4-methanesulfonyloxy-cyclohexanecarboxylic acid methyl ester
(105): To a stirred solution of the alcohols 102, 103 (3.5 g, 17 mmol) and
dimethylaminopyridine (200 mg, 1.7 mmol) in dry CH2Cl2 (240 mL) was added freshly
distilled Et3N (3.4 mL, 25 mmol) followed by methanesulfonyl chloride (3.2 mL, 33
mmol). The mixture was refluxed under an atmosphere of nitrogen for 41 h. The
reaction was allowed to cool to room temperature. The organic layer was washed with
5% NaHCO3 (aq), dried over Na2SO4, and condensed under reduced pressure. The
resulting solid was triturated with EtOAc to yield the mesylate as a white solid (1.9 g,
42% yield). 1H NMR (CDCl3): δ 5.67 (br s, NH), 4.92 (m, 1H), 3.74 (s, 3H), 3.05 (s,
3H), 2.27 (t, J = 10.8, 2 H), 2.06-1.95 (m, 4H), 2.06 (s, 3H), 1.88-1.81 (m, 2H).

13

C

NMR (CDCl3): 173.5, 170.2, 79.0, 58.12, 52.8, 39.0, 27.6 (2), 27.2 (2), 23.5.

7-Acetyl-7-azabicyclo[2.2.1]heptane-1-carboxylic acid methyl ester (106): To a
stirred solution of the mesylate 105 (1.6 g, 5.9 mmol) in dry THF (55 mL) was added a 1
M solution of potassium tert-butoxide in THF (12 mL, 1M) at –78 ºC over 20 minutes.
The reaction was stirred at –78 ºC for 80 min. The ice bath was removed and the reaction
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was stirred for 20 h at room temperature. The reaction was quenched with 0.5 M HCl (25
mL) and extracted with EtOAc (3 × 50 mL). The organic layers were combined, dried
over Na2SO4, and concentrated. The residue was purified by gravity column
chromatography (SiO2, EtOAc) to afford 106 as a white solid (170 mg, 15% yield). 1H
NMR (CDCl3): δ 4.24 (t, 1H), 3.81 (s, 3H), 2.27-2.20 (m, 2H), 2.05 (s, 3H), 1.97-1.77
(m, 2H), 1.77-1.72 (m, 2H), 1.63-1.57 (m, 2H). 13C NMR (CDCl3): δ 171.5, 171.3, 66.9,
59.5, 52.4, 32.4 (2), 30.4 (2), 21.7. Anal. Calc. for C10H15NO3: C, 60.9; H, 7.67; N, 7.1
Found: C, 60.1; H, 7.72; N, 7.0

3-Hydroxy-2-(toluene-4-sulfonylamino)-propionic acid (110): To a stirred solution of
L-Serine (5.0 g, 48 mmol) and Na2CO3 (14 g, 130 mmol) in deionized water (150 mL)
was added toluenesulfonylchloride (11 g, 55 mmol). The mixture was stirred vigorously
at 25 ºC for 4 h. The solution was then filtered to removed NaCl and the filtrate was
acidified to pH = 2 with ice cold concentrated HCl. The product was collected and
washed with water and ethanol to yield the tosylate 110 as a pure white solid (7.9 g, 84%
yield) mp 240-242 ºC, (dec.) 1H NMR (CDCl3): δ 7.76 (d, J = 8.4 Hz, 2H), 7.34 (d, J =
8.0 Hz, 2H), 3.90 (t, J = 7.2 Hz, 1H), 3.78-3.66 (m, 2H) 2.41 (s, 3H). Anal. Calc. for
C10H13NO5S: C, 46.32; H, 5.05; N5.40. Found: C, 46.31; H, 5.09; N, 5.39.

3-Hydroxy-2-(toluene-4-sulfonylamino)-propionic acid methyl ester (111):
Anhydrous HCl (g) was bubbled through MeOH (300 mL) for 45 minutes. The
methanolic HCl (300 mL) was added to a solution of 110 (1.0 g, 3.9 mmol) and the
mixture was heated to reflux for 24 h. The solvent was removed and the residue
dissolved in EtOAc. The organic layer was washed with saturated Na2CO3 (200 mL) and
the aqueous phase was extracted with EtOAc (3 × 150 mL). The organic fractions were
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combined and dried over Na2SO4 followed by evaporation under reduced pressure to
yield a white solid (3.8 g, 94% yield), mp 71-73 ºC. 1H NMR (CDCl3): δ 7.75 (d, J = 8.4
Hz, 2H), 7.28 (d, J = 8.4 Hz, 2H), 4.03 (t, J = 4, 1H) 3.85 (qd, J 1= 12.6, J2 = 4 2H), 3.55
(s, 3H), 2.40 (s, 3H).
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C NMR (CDCl3): δ 170.5, 144.0, 136.7, 129.9 (2), 127.4 (2),

63.8, 57.8, 53.0, 21.7. Anal. Calc. for C11H15O5NS: C, 48.34; H, 5.53; N, 5.12. Found:
C, 48.51; H, 5.58; N, 5.16.

3-Methanesulfonyloxy-2-(toluene-4-sulfonylamino)-propionic acid methyl ester
(113): To a stirred solution of the alcohol 109 (1.0 g, 3.6 mmol) and
dimethylaminopyridine (4 mg) in dry CH2Cl2 (50 mL) was added distilled triethylamine
(0.76 mL, 5.5 mmol) and methanesulfonylchloride (1.5 mL, 0.35 mL) dropwise at 0 ºC.
The solution was allowed to come to ambient temperature and stirred for 36 h. The
organic layer was washed with deionized H2O (1 × 50 mL) and with 5% Na2CO3 (2 × 50
mL), dried over Na2SO4, and condensed under reduced pressure. The mesylate 113 was
recrystallized from EtOAc to afford a white solid (1.1 g, 91%). 1H NMR (CDCl3): δ 7.74
(d, J = 8.4 Hz, 2H), 7.32 (d, J = 8.4 Hz, 2H), 5.59 (d, J = 7.6 Hz, NH), 4.56-4.52 (m, 1H),
4.54-4.42 (m, 1H), 4.21-4.18 (m, 1H), 3.68 9s, 3H), 3.04 (s, 3H), 2.43 (s, 3H).
N- (tert-Butoxycarbonyl)-O-tosyl-d,l-serine Methyl Ester (116): To a stirred solution
of p-toluenesulfonic acid (23 g, 0.12 mol) in dry pyridine (30 mL) was added N-tertbutoxycarbonyl-d-serine methyl ester (20 g, 0.09 mol) dissolved in dry pyridine (70 mL)
at –15 ºC. The mixture was stirred at this temperature for 6 h and then 0 ºC overnight.
The heterogenous mixture was poured over crushed ice. The aqueous mixture was
extracted with EtOAc (2 × 100 mL) and combined organic fractions were washed with
20% citric acid (100 mL), saturated NaHCO3 (100 mL), and brine (2 × 100 mL). The
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organic layer was washed again with ice cold 1N HCl (100 mL), saturated NaHCO3 (100
mL), and brine (2 × 100 mL). The solution was dried over Na2SO4 and the solvent
removed under reduced pressure. The golden yellow oil was dried on a high vacuum
pump until it solidified. The pale yellow solid was then recrystallized from pure EtOAc
at 0 ºC to yield the product as a white crystalline solid (28 g, 87% yield), mp 72 ºC. 1H
NMR (CDCl3, 400 MHz) δ 7.76 (d, J = 8.4 Hz, 2H), 7.35 (d, J = 8.4 Hz, 2H), 5.29 9 (br
s, NH), 4.51 (d, J = 8, 1H), 4.40 (dd, J1 = 10.6, J = 2.8, 1H), 4.28 (dd, J1 = 10.6, J = 2.8,
1H), 3.70 (s, 3H), 2.43 (s, 3H), 1.42 (s, 9H). 13C NMR (CDCl3, 400 MHz): 172.0, 152.5,
131.9, 130.7, 127.8, 70.6, 62.5, 55.8, 50.4, 28.7, 20.9. Anal. Calc. for C9H15O4N: C,
51.46; H, 6.21; N, 3.75. Found: C, 51.44; H, 6.20; H, 3.88.

2-tert-Butoxycarbonylamino-acrylic acid methyl ester (117). To a stirred solution of
116 (12. g, 0.03 mol) in dry CH2Cl2 (350 mL) under an inert atmosphere DBU (6.0 mL,
0.08 mol) was added dropwise at 0 ºC. The reaction was stirred at 0 ºC until no more
starting material was visible by TLC (6 h). The reaction was quenched and washed with
water. The combined organic fractions were dried over Na2SO4 and concentrated under
reduced pressure. The product was purified by flash chromatography (SiO2 to yield a tan
solid (6.6 g, 98%) 1H NMR (CDCl3, 400 MHz): δ 7.04 (br s, NH), 6.16 (s, 1H), 5.72 (s,
1H), 3.83 (s, 3H)1.49 (s, 9H).
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C NMR (CDCl3, 400 MHz): 164.5, 152.6, 131.4, 105.2,

80.6, 52.9, 28.2. Anal. Calc. for C9H15O4N: C, 53.72; H, 7.51; N, 6.96.

1-tert-Butoxycarbonylamino-4-oxo-cyclohex-2-enecarboxylic acid methyl ester
(120): To a solution of Danishefsky’s Diene (20 g, 0.12 mol) in dry toluene (360 mL)
under an atmosphere of nitrogen was added a solution of the acrylate 117 (6.0 g, 0.03
mol) in dry toluene (30 mL). The solution was heated to reflux for 24 h and then an
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additional equivalent of the dienophile (6.0 g, 0.03 mol) in toluene (30 mL) was added.
The reaction mixture was then heated to reflux for an additional 48 h. The toluene was
removed under reduced pressure and the resulting residue was dissolved in a soultion of
1:4 0.005 M HCl :THF (60 mL: 240 mL). The solution was then stirred at room
temperature for 15 h. After the hydrolysis of the trimethylsilyl group was completed by
TLC, the THF was removed under reduced pressure. The crude material was dissolved in
CH2Cl2 (160 mL), washed with brine (2 × 160 mL) and then saturated NaHCO3 (2 × 160
mL). The aqueous layers were then extracted with CH2Cl2 (2 × 160 mL) and EtOAc (2 ×
160 mL). The organic fractions were combined and dried over Na2SO4 and condensed to
an amber oil. This was brought to the next step without purification. To a stirred
solution of the residue in dry CH2Cl2 (320 mL) under an atmosphere of nitrogen DBU
(9.8 mL) was added dropwise at 0 ºC. The mixture was stirred at room temperature for
24 h. When the elimination of the methoxy group was complete by TLC, the organic
layer was washed with 0.5 M HCl (200 mL) and the aqueous layer extracted with CH2Cl2
(5 × 50 mL). The organic fractions were combined, dried over Na2SO4, and
concentrated. The brown oil was purified by gradient column chromatography (SiO2,
CHCl3: MeOH, 9:1) to afford 120 (9.7 g, 60% yield) as an amber oil. This could be
recrystallized in pure EtOAc to give a colorless solid. 1H NMR (CDCL3) δ 7.05 (d, J =
10.4 Hz, 1H), 6.11 (d, J= 10.4 Hz, 1H), 5.36 (br s, NH), 3.81 (s, 3H), 2.55 (t, J = 6.4,
2H), 2.46-2.30 (m, 2H), 1.45 (s, 9H).

13

C NMR (CDCl3): 197.4, 171.2, 170.2, 147.1,

129.9, 57.8, 53.1, 33.5, 31.4, 22.7. Anal. Calc. for C13H19NO5: C, 57.98; H, 7.11; N,
5.20.
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1-tert-Butoxycarbonylamino-4-oxo-cyclohexanecarboxylic acid methyl ester (121):
The enone 120 (3.0 g) was hydrogenated (1 atm) over PtO2 (30 mg) in CH2Cl2 (150 mL)
for 48 h. The solution was filtered through a pad of Celite. The solvent was removed
under reduced pressure and the resulting residue was recrystallized from hexane:EtOAc
(1:9) to yield 121 as a white solid (2.7 g, 89% yield) mp 116-118 ºC. 1H NMR (CDCl3):
δ 3.76 (s, 3H), 2.57-2.25 (m, 8H), 1.45 (s, 9H).

13

C NMR (CDCl3): δ 209.1, 173.9, 155.3,

57.9, 52.6, 36.5, 32.7 (2), 28.2 (2). Analysis calculated for C13H21NO5: C, 57.55; H, 7.80;
N, 5.16. Found: C, 57.30; H, 7.73; N, 5.08.

1-tert-Butoxycarbonylamino-4-hydroxy-cyclohexanecarboxylic acid methyl ester
(122): To a solution of the ketone 121 (5.1 g, 19 mmol) in dry THF (180 mL) under an
atmosphere of nitrogen at –78 ºC was added a 1 M solution of L-Selectride (2.8 mL, 1 M)
over 25 minutes. The reaction was stirred at this temperature for 6 h. The reaction was
quenched by the addition of saturated NH4Cl (100 mL) and the mixture was allowed to
come to room temperature. The solvent was removed under reduced pressure to afford a
yellow residue. This was chromatographed (SiO2 CHCl3: MeOH 9.5:0.5) to give the
mixture of alcohols (cis:trans 1:9) as a white solid (5.2 g, 87% yield). Data for the trans
isomer: 1H NMR (CDCl3): δ 4.81 (br s, NH), 3.94 (br s, OH), 3.73 (s, 3H), 2.25-2.30 (m,
1H), 1.88-1.66 (m, 8H), 1.43 (s, 9H).

13

C NMR (CDCl3): δ 174.9, 155.3, 69.2, 66.1,

58.6, 52.3, 30.2, 29.0, 28.4.

4-Hydroxy-1-(toluene-4-sulfonylamino)-cyclohexanecarboxylic acid methyl ester
(123): To a stirred solution of 122 (310 mg, 1.2 mmol) in EtOAc (previously dried over
Na2SO4) under an atmosphere of nitrogen was added MeOH (0.9 mL, 2.3 mmol)
followed by the careful, dropwise addition of acetyl chloride (0.9 mL, 1.2 mmol) at 0 ºC.
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The reaction was stirred at ambient temperature overnight. The solvent was removed
under reduced pressure to afford the quaternary ammonium salt as a white powder (180
mg, 75%, crude yield). The solid was triterated with EtOAc and dried thoroughly under
vacuum. The recrystallized material was used in the following tosylation reaction
without further purification. To a stirred solution of the crude salt (250 mg, 1.2 mmol) in
dry CH3CN (5 mL) was added a solution of KOH (160 mg, 3.0 mmol) in CH3CN (5 mL)
at 0 ºC. Triethylamine (.03 mL, .12 mmol) and a solution of tosyl chloride (270 mg, 1.4
mmol) in CH3CN (5 mL) were added dropwise to the stirred solution. The mixture was
stirred at room temperature overnight until the reaction was complete by TLC. The
solvent was removed under reduced pressure and the residue dissolved in CH2Cl2 (20
mL). The organic solution was washed with deionized H2O. The aqueous layer was
extracted with methylene chloride (2 × 20 mL). The combined organic fractions were
dried over Na2SO4 and concentrated under reduced pressure. The resultant oil was
purified by column chromatography (SiO2, 9.5 CHCl3: 0.5 MeOH) to afford the
sulfamide 124 as a brown oil (270 mg, 69 % yield): 1H NMR (CDCl3, 400 MHz): δ 7.73
(d, J = 8.4 Hz, 2H), 7.29 (d, J = 8.4 MHz, 2H), 5.31, (br s, NH), 3.81 (m, 1H) 3.46 (s,
3H), 2.42 (s, 3H), 2.23-2.17 (m, 2H), 1.75-1.67 (m, 4H), 1.50-1.43 (m, 2H).

7-(Toluene-4-sulfonyl)-7-azabicyclo[2.2.1]heptane-1-carboxylic acid methyl ester
(125): To a stirred solution of triphenylphosphine (41 mg, 0.16 mmol) in dry THF (1
mL) under an atmosphere of nitrogen was added a solution of 123 (34 mg, 0.10 mmol) in
dry THF (3 mL). DEAD (diethylaminodicarboxylate) (30 µL, 0.02 mmol) was added
slowly to the reaction mixture. The reaction was stirred at room temperature for 48 h.
The THF was removed under reduced pressure. The resulting residue was purified by
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column chromatography (SiO2, CHCl3) to yield a white solid 125 in poor yield (6 mg, 18
%) 1H NMR (CDCl3, 400 MHz): δ 7.80 (d, J = 8 Hz, 2H), 7.28 (d, J = 8 MHz, 2H), 4.32,
(t, J = 4.8 Hz, 1H), 3.73 (s, 3H), 2.42 (s, 3H), 2.35-2.26 (m, 2H), 2.07-1.98 (m, 2H), 1.831.77 (m, 2H), 1.56-1.49 (m, 2H). 13C NMR (CDCl3): δ 173.0, 143.9, 137.6, 129.7 (2),
127.5 (2), 60.2, 52.5, 38.7, 27.3, 26.3, 21.6.

Acetic acid 4-methanesulfonyloxy-1-(toluene-4-sulfonylamino)-cyclohexyl ester
(126). To a stirred solution of the 124 alcohol (266 mg, 0.78 mmol) in dry CH2Cl2 (10
mL) under an atmosphere of nitrogen was added freshly distilled diisopropylethylamine
(DIEA) (0.27 mL, 1.6 mmol) followed by addition of methanesulfonyl chloride (0.15
mL, 0.16 mmol). The mixture was stirred at room temperature for 36 h. The organic
layer was washed with 5% NaHCO3 (aq), dried over Na2SO4, and condensed under
reduced pressure. The resulting solid was triturated with EtOAc to yield the mesylate

126 as a tan solid (109 mg, 33% yield). 1H NMR (CDCl3): δ 7.74 (d, J = 8.4 Hz, 2H)
7.30 (d, J = 8.4 Hz, 2H) 4.99 (br s, NH), 4.84 (m, 1H), 3.47 (s, 3H), 2.99 (s, 3H), 2.43 (s,
3H) 2.15-2.08 (m, 2H), 1.92-1.80 (m, 4H). 13C NMR (CDCl3): δ 173.3, 144.1, 137.8,
129.9 (2), 127.6 (2), 60.4, 52.7, 38.9, 27.8 (2), 26.5 (2), 21.7.

7-(Toluene-4-sulfonyl)-7-azabicyclo[2.2.1]heptane-1-carboxylic acid methyl ester
Method B:

To a stirred solution of the mesolate 126 (1.60 g, 5.9 mmol) in dry THF

(55 mL) under an atmosphere of nitrogen at –78 ºC was added a solution of potassium
tert-butoxide in THF (11.7 mL, 1 M) over 20 minutes. The reaction was stirred at –78
ºC for 80 min. The reaction was stirred for an additional 20 h at 20 ºC. The reaction was
quenched with 0.5 M HCl (25 mL) and was extracted with EtOAc (3 × 50 ml). The
organic layers were combined, dried over Na2SO4, and condensed. 1H NMR (CDCl3, 400
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MHz): δ 7.80 (d, J = 8 Hz, 2H), 7.28 (d, J = 8 MHz, 2H), 4.32, (t, J = 4.8 Hz, 1H), 3.73
(s, 3H), 2.42 (s, 3H), 2.35-2.26 (m, 2H), 2.07-1.98 (m, 2H), 1.83-1.77 (m, 2H), 1.56-1.49
(m, 2H).

Benzoic acid 2-benzoylamino-2-methoxycarbonyl-ethyl ester (127): To a stirred
solution of d,l serine methylester (4.5 g, 29 mmol) in dry CH2Cl2 (150 mL) under an
atmosphere of nitrogen was added distilled triethylamine (13 mL, 98 mmol) and benzoyl
chloride (7.7 mL, 67 mmol) in alternating portions of 2 mL triethylamine followed by 1
mL benzoyl chloride at 0 ºC. The reaction was stirred at room temperature for 7 h. The
reaction was then washed with saturated NaHCO3 (2 × 50 mL) and the organic layer was
dried over Na2SO4 and condensed to yield 127 as a white solid (9.1 g, 97% yield). 1H
NMR (CDCl3, 400 MHz): δ 8.00 (d, J = 7.20 Hz, 2H), 7.82 (d, J = 7.2 Hz, 2H), 7.60-7.43
(m, 6H), 7.07 (d, J = 6.8 Hz, 1H), 5.19, (q, J = 4 Hz, 1H), 4.78 (d, J = 3.6 Hz, 2H), 3.84
(s, 3H).

2-Benzoylamino-acrylic acid methyl ester (128). To a stirred solution of 127 (9.1 g, 28
mmol) dry CH2Cl2 (300 mL) under an inert atmosphere of nitrogen DBU (5.1 mL, 0.07
mol) was added dropwise at 0 ºC. The reaction was stirred at 0 ºC for 6 h. When the
elimination was completed by TLC, the reaction was quenched and washed with water
(300 mL). The combined organic fractions were dried over Na2SO4 and concentrated
under reduced pressure. The product was purified by flash chromatography (SiO2 6:4
hexanes:EtOAC) to yield 128 as a thick, brown oil (5.9 g, 99% yield). 1H NMR (CDCl3,
400 MHz): δ 8.54 (br s, NH), 7.84 (d, J = 7.6 Hz, 2H) 7.55-7.46 (m, 3H), 6.80 (s, 1H),
6.00 (s, 1H), 3.90 (s, 3H).
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C NMR (CDCl3, 400 MHz): 165.5, 164.5, 134.0, 131.8,

130.8, 126.8, 126.7, 108.6, 52.9.
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1-Benzoylamino-4-oxo-cyclohex-2-enecarboxylic acid methyl ester (131): To a stirred
solution of Danishefsky’s Diene (6.5 mL, 33 mol) in dry toluene (80 mL) under an
atmosphere of nitrogen was added a solution of the acrylate 128 (1.7 g, 8.3 mmol) in dry
toluene (20 mL). The solution was heated to reflux for 24 h and then an additional
equivalent of the dienophile (1.7 g, 8.3 mmol) in toluene (20 mL) was added. The
reaction mixture was heated to reflux for an additional 48 h. The toluene was removed
under reduced pressure and the resulting residue was dissolved in a solution of 1:4 0.005
M HCl :THF (40 mL). The solution was then stirred at room temperature for 15 h. After
the hydrolysis of the trimethylsilyl group was complete (TLC), the THF was removed
under reduced pressure. The crude material was dissolved in methylene chloride (160
mL), washed with brine (2 × 160 mL) and saturated NaHCO3. The aqueous layers were
then extracted with CH2Cl2 (2 × 160 mL) and EtOAc (2 × 160 mL). The organic
fractions were combined and dried over Na2SO4 and condensed to an amber oil. The
material was carried on to the next step without purification. The residue was dissolved
in dry CH2Cl2 (180 mL) under an atmosphere of nitrogen. DBU (5.4 mL) was added
dropwise at 0 ºC. The mixture was stirred at room temperature for 24 h. When the
elimination of the methoxy group was completed by TLC, the organic layer was washed
with 0.5 M HCl (120 mL) and the aqueous layer extracted with CH2Cl2 (5 × 60 mL). The
organic fractions were combined, dried over Na2SO4, and concentrated. The brown oil
was purified by gradient column chromatography (SiO2, hexanes:EtOAc, 1:1) to afford

131 (5.4, 60% yield over 3 steps) as an yellow oil. This was recrystallized from EtOAc
to give a colorless solid. 1H NMR (CDCL3) δ 7.80 (d, J = 6.8 Hz, 2H), 7.57-7.44 (m, 3H)
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7.14 (d, J= 10.4 Hz, 1H), 6.89 (br s, NH), 3.85 (s, 3H), 2.66-2.54 (m, 4H), 1.45.
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C

NMR (CDCl3): 197.4, 171.2, 170.2, 147.1, 129.9, 57.8, 53.1, 33.5, 31.4, 22.7.

1-Benzoylamino-4-oxo-cyclohexanecarboxylic acid methyl ester (132): The enone
131(5.4 g 20 mmol) was hydrogenated (1 atm, H2) over 10% Pd/C (1.4 g) in CH2Cl2 (270
mL) for 48 h. The solution was filtered through a pad of Celite and the solvent was
removed under reduced pressure. The resulting residue was recrystallized from
hexane:EtOAc (1:9) to yield 132 as a white solid (5.1 g, 92.% yield), mp 133.134 ºC. 1H
NMR (CDCl3): δ 7.80 (d, J = 6.8 Hz, 2H), 7.56-7.45 (m, 3H), 6.39 (br s, NH) 3.80 (s,
3H), 2.78-2.52 (m, 8H).

1-tert-Butoxycarbonylamino-4-hydroxy-cyclohexanecarboxylic acid methyl ester
(133): To a stirred solution of the ketone 132 (5.1 g, 18 mmol) in dry THF (100 mL)
under an atmosphere of nitrogen at –78 ºC was added a solution of L-Selectride (22 mL,
1 M) over 25 minutes. The reaction was stirred at this temperature for 3 h. Saturated
NH4Cl (25 mL) was added to quench the mixture was allowed to come to room
temperature. The solutiuon was filtered and condensed under reduced pressure at room
temperaure. The residue was washed with EtOAc (50 mL) and a 1:3 mixture of
isopropanol: CHCl3 (2 × 60). The resulting residue was chromatographed (SiO2
hexanes:EtOac 1:9) to give the mixture of alcohols 133, 143 (cis:trans 1:9) as a white
solid (5.3 g, 86% yield) Isomer ratio was determined by 1H NMR peak integration. Data
for the desired trans product 133 is as follows: 1H NMR (CDCl3): δ 7.80 (d J = 6.8 Hz,
2H) 7.56-7.45 (m, 3H), 6.22 (br s, NH), 3.98 (m, 1H), 3.77 (s, 3H), 2.50-2.41 (m, 2H),
1.97-2.05 (m, 2H), 1.72-1.80 (m, 4H).
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1-Benzoylamino-4-methanesulfonyloxy-cyclohexanecarboxylic acid methyl ester
(135): To a stirred solution of the alcohols 133, 134 (3.8 g, 14 mmol) in dry CH2Cl2 (100
mL) under an atmosphere of nitrogen was added diisopropylethylamine (DIEA) (4.7 mL,
27 mmol) followed by methanesulfonyl chloride (2.1 mL, 27 mmol). The mixture was
stirred at room temperature for 36 h. The resulting solid chromatographed by gravity
column chromatography (SiO2, hexanes:EtOAc 1:1) to isolate the trans isomer 135 as a
white solid (4.4 mg, 90% yield). 1H NMR (CDCl3): δ 7.76 (d, J = 7.2 Hz, 2H) 7.54 (t, J
= 7.6 Hz, 1H) 7.45 (t J = 8.0 Hz, 2H), 6.20 (br s, NH), 4.97 (m, 1H), 3.77 (s, 3H), 3.06 (s,
3H), 2.42-2.34 (m, 3H) 2.18-2.08 (m, 4H), 1.96-1.89 (m, 2H). 13C NMR (CDCl3): δ
173.3, 144.1, 137.8, 129.9 (2), 127.6 (2), 60.4, 52.7, 38.9, 27.8 (2), 26.5 (2), 21.7.

7-Benzoyl-7-azabicyclo[2.2.1]heptane-1-carboxylic acid methyl ester (137): To a
stirred solution of the mesylate (2.4 g, 6.8 mmol) in dry THF (70 mL) under an
atmosphere of nitrogen was added a solution of KOtBu in THF (7.4 mL, 1 M) at –78 ºC
over 20 minutes. The reaction was stirred at –78 ºC for 80 min and then stirred for 16 h
at 20 ºC. The reaction was quenched with 0.5 M HCl (8 mL) and the aqueous layer
extracted with EtOAc (1 × 60 ml) and CH2Cl2 (2 × 60 mL). The organic layers were
combined, dried with Na2SO4, and the THF removed under reduced pressure. The oil
was dissolved in benzene and the solvent was removed under reduced pressure to yield

137 a white solid (2.3 g, 67% yield) mp 100-102 ºC. 1H NMR (CDCl3, 400 MHz): δ 7.65
(dd, J1 = 8.2 Hz J2 = 1.2 Hz, 2H), 7.51-7.39 (m, 3H), 4.27, (t, J = 4.8 Hz, 1H), 3.82 (s,
3H), 2.39-2.33 (m, 2H), 1.96-1.90 (m, 2H), 1.85-1.79 (m, 2H), 1.59-1.53 (m, 2H). 13C
NMR (CDCl3): δ 172.3, 171.5, 134.6, 131.4, 128.6, 67.5, 61.2, 52.4, 32.1, 30.4. Anal.
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Calc. for C15H17NO3·1/8 H2O: C, 68.88; H, 6.74; N, 5.34. Found: C, 68.90; H, 6.75; N,
5.24.

1-Hydroxymethyl-7-benzoyl-azabicyclo[2.2.1]heptane (140): To a stirred solution of
the methyl ester 137 (0.47 g, 1.8 mmol) in dry THF (20 mL) under an atmosphere of
nitrogen was added a solution of LiBH4 in THF (1.4 mL, 2 M) at 0 ºC. The reaction was
stirred at room temperature for 24 h. At this time an additional 0.5 eq of LiBH4 (0.7 mL,
2 M) was added. The reaction mixture was then stirred for an additional 24 h at 25 ºC.
When the reduction was completed by TLC, 0.5 M HCl (10 mL) was added to neutralize
the reaction mixture. The solution was extracted with EtOAc (3 × 20 mL) and the
organic fractions dried over Na2SO4, filtered and evaporated under reduced pressure. The
resulting solid was purified by gravity column chromatography (SiO2, hexanes:EtOAc
1:1) to yield a pale yellow crystalline solid (0.24 g, 58% yield) mp 75-77 ºC. 1H NMR
(CDCl3, 400 MHz): δ 7.48-7.39 (m, 5H) 5.58 (t, J = 7.2 Hz, 1H), 4.11 (t, 1H), 4.01 (d, J
= 7.2 Hz, 2H), 2.08-2.03 (m, 2H), 1.87-1.84 (m, 2H), 1.57-1.50 (m, 4H).

13

C NMR

(CDCl3): δ 168.4, 136.8, 130.5, 128.6 (2), 127.3 (2), 71.0, 61.5, 61.3, 31.3, 29.7. Anal.
Calc. for C15H17NO3·1/8 H2O: C, 72.00; H, 7.44; N, 6.00. Found: C, 71.85; H, 7.37; N,
5.94.

Methanesulfonic acid 7-benzoyl-7-aza-bicyclo[2.2.1]hept-1-yl-methyl ester (143):
To a stirred solution of the alcohol 140 (0.25 g, 1.1 mmol) in CH2Cl2 (25 mL) was added
triethylamine (0.22 mL) and methanesulfonyl chloride (0.09 mL) at 0 ºC for 36 h. The
organic layer was washed with H2O and brine. The organic layer was dried over Na2SO4
and condensed. The mesylate 143 was used without further purification in the following
reactions.

116

7-Benzoyl-[1-(pyridin-3-yloxymethyl)-7-azabicyclo[2.2.1]heptane (147): To a stirred
solution of 60% NaH dispersion in mineral oil (.07 g, 1.8 mmol,) in dry DMF (20 mL)
under an atmosphere of nitrogen was added a solution of 3-hydroxypyridine (0.13 g, 1.3
mmol) in DMF (10 mL). The solution was stirred for 1 h at 25 ºC. A solution of the
mesylate 143 (0.27 g, 0.83 mmol) in DMF (10 mL) was added and the reaction was
stirred at 80 ºC for 24 h. The DMF was removed under reduced pressure and the dark
brown residue was purified by column chromtography (SiO2, CHCl3:MeOH 98:2) to
afford 147 as a white solid (0.24g, 94% yield), mp 79-80 ºC. 1H NMR (CDCl3, 400
MHz): δ 8.41 (d, J = 4.8 Hz, 1H) 8.26 (d, J = 4.8 Hz 1H) 8.54 (m, 2H) 7.46-7.39 (m, 3H)
7.31-7.27 (m, 1H) 7.23-7.20 (m, 1H) 4.88 (s, 1H), 4.21 (t, 1H), 2.10-2.02 (m, 2H), 1.951.89 (m, 4H), 1.58-1.53 (m, 2H).

13

C NMR (CDCl3): δ 170.7, 155.5, 142.2, 138.9, 136.9,

130.8, 128.5 (2), 127.9 (2), 124.0, 121.0, 71.6, 67.5, 61.6, 33.2 (2), 29.9 (2). Anal. Calc.
for C19H20N2O3·1/4 H2O: C, 72.01; H, 6.52; N, 8.84. Found: C, 72.01; H, 6.45; N, 8.86.

7-Benzoyl-[1-(pyridin-2-yloxymethyl)-7-aza-bicyclo[2.2.1]heptane] (148a): To a
stirred solution of 60% NaH dispersion in mineral oil (0.13 g, 3.3 mmol,) in dry DMF (30
mL) under an atmosphere of nitrogen was added a solution of 2-hydroxypyridine (0.25 g,
2.7 mmol) in DMF (20 mL). The solution was stirred for 1 h at 25 ºC. A solution of the
mesylate 143 (0.41 g, 1.3 mmol) in DMF (10 mL) was added and the reaction was stirred
at 80 ºC for 24 h. The DMF was removed under reduced pressure and the dark brown
residue was purified by column chromtography (SiO2, CHCl3:MeOH 98:2) to furnish a
white solid (200 mg, 51% yield) mp 135-137 ºC and the 2-pyridinone isomer 148b as a
crystalline solid (50 mg, 12%) mp 142 ºC. 1H NMR (CDCl3, 400 MHz): δ 8.15 (d, J =
4.8 Hz, 1H), 7.58-7.51 (m, 2H) 7.42-7.34 (m, 3H), 6.83 (t, J = 6 Hz, 1H) 6.75 (d, J = 8.4
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Hz, 1H), 4.88 (s, 1H), 5.12 (s 2H), 4.21 (t, J = 4 Hz, 1H) 2.13-2.07 (m, 2H), 1.90-1.74
(m, 4H), 1.53-1.47 (m, 2H).

13

C NMR (CDCl3): δ 170.5, 164.0, 147.0, 138.6, 137.2,

130.4, 128.3 (2), 127.9 (2), 116.8, 110.9, 67.5, 66.9, 61.4, 53.8, 32.9 (2), 29.9 (2). Anal.
Calc. for C19H20N2O2: C, 74.00; H, 6.54; N, 9.08. Found: C, 73.90; H, 6.57; N, 9.13.

1-(7-Benzoyl-7-azabicyclo[2.2.1]hept-1-ylmethyl)-1H-pyridin-2-one (148b): 1H NMR
(CDCl3, 400 MHz): δ 7.23 (dd, J1 = 7, J2 = 1.6 Hz, 1H), 7.58 (d, J = 6.8 Hz, 2H), 7.507.47 (m, 1H), 7.42 (t, J = 8 Hz, 2H), 7.34-7.28 (m, 2H), 6.58 (d, J = 9.2, 1H), 6.11 (td, J1
= 6.8 Hz J2 = 1.6 Hz, 1H), 5.14 (s, 2H), 4.13 9t, J = 4.4 Hz, 1H), 1.96 (m, 2H), 1.82-1.70
(m, 4H), 1.49-1.43 (m, 2H). 13C NMR (CDCl3): δ 173.8, 163.4, 139.7, 138.7, 137.0,
128.6 (2), 128.0 (2), 120.8, 106.1, 69.0, 62.7, 48.0, 32.6, 29.5. Anal. Calc. for
C19H20N2O2: C, 74.00; H, 6.54; N, 9.08. Found: C, 73.90; H, 6.57; N, 9.13.

7-Benzoyl(6-Chloro-pyridin-3-yloxymethyl)-7-aza-bicyclo[2.2.1]heptane (149): To a
stirred solution of 60% NaH dispersion in mineral oil (0.04 g, 0.9 mmol,) in dry DMF (5
mL) under an atmosphere of nitrogen was added a solution of 3-hydroxy-5chloropyridine (90 mg, 0.67 mmol) in DMF (5 mL). The solution was stirred for 1 h at
25 ºC. A solution of the mesylate (0.14 g, 0.44 mmol) in DMF (10 mL) was added and
the reaction was stirred at 80 ºC for 24 h. The DMF was removed under reduced pressure
and the dark brown residue was purified by column chromtography (SiO2,
hexanes:EtOAc 3:1) to elude a white solid (140 mg, 93% yield), mp 85 ºC. 1H NMR
(CDCl3, 400 MHz): δ 8.12 (s, 1H) 7.55 (d, J = 6.8 Hz 2H), 7.48-7.38 (m, 3H) 7.31-7.27
(m, 1H) 7.22 (m, 1H) 4.80 (s, 2H), 4.21 (t, 1H), 2.10-2.04 (m, 2H), 1.94-1.85 (m, 4H),
1.58-1.52 (m, 4H).

13

C NMR (CDCl3): δ 170.8, 154.8, 142.7, 137.6, 136.7, 130.9, 128.6
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(2), 127.9 (2), 125.0, 124.6, 71.0, 67.4, 61.7, 33.1 (2), 29.9 (2). Anal. Calc. for
C19H19N2O2·1/4 H2O: C, 72.01; H, 6.52; N, 8.84. Found: C, 72.01; H, 6.45; N, 8.86.

6-Chloro-pyridin-3-ol (146): To a stirred solution of 3-amino-5-chloropyridine (.500 g,
3.9 mmol) in a 3:1 THF:CH2Cl2 solution (40 mL) was added BF3·(CH3CH2O) (1.2 g, 8.3
mmol) followed by tert-butyl nitrite (0.48 g, 4.7 mmol) at –10 ºC. The reaction was
stirred for 10 min at –10 ºC then 0 ºC for 30 min. Pentane was then added to the reaction
mixture. The resulting diazonium salt precipitate was collected by suction filtration and
washed with cold pentane resulting in an orange solid that was used in the next step
without further purification. The salt was dissolved in acetic anhydride (6 mL) and
stirred at 75 ºC for 3 h until N2 evolution was complete. The crude product was purified
by flash chromatography (SiO2, EtOAc:hexanes 3:7) to yield a yellow oil (0.11g, 16 %
yield over 2 steps) 1H NMR (CDCl3, 400 MHz): δ 8.22 (d, J = 2.4 Hz, 1H), 7.47 (dd, J1 =
8 Hz, J2 = 2.8 Hz, 1H), 7.35 (d, J = 8.8 Hz, 1H), 2.34 (s, 3H).
To a stirred solution of the acetate (0.11 g) in MeOH (5 mL) was added K2CO3 (0.04 g,
0.32 mmol). The reaction was stirred at ambient temperature for 8 h. When the reaction
was complete by TLC, the solvent was removed under reduced pressure. The residue
was dissolved in H2O and extracted with Et2O (3 × 15 mL). The organic layer was dried
with Na2SO4 and condensed to yield 146 as a pure white solid (80 mg, 99% yield). 1H
NMR (CDCl3, 400 MHz): δ 8.04 (s, 1H), 7.26 (s, 1H), 7.22 (s, 1H).

1-(Pyridin-3-yloxymethyl)-7-azabicyclo[2.2.1]heptane (153): The amine 147 (0.18 g,
0.05 mmol) was dissolved in a 2N KOH solution in 3:1 MeOH/H2O (15 mL) and heated
to reflux for 48 h. When no starting material was detected by TLC, water was added to
the reaction mixture and the MeOH was removed under reduced pressure. The remaining
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aqueous mixture was extracted with CH2Cl2 (5 × 50 mL) and the combined organic layers
dried over Na2SO4 and condensed to yield 153 a yellow oil (120 mg, 99% yield).

1

H

NMR (CDCl3, 400 MHz): δ 8.34 (s, 1H), 8.21 (d, J = 2.8 Hz, 1H), 7.25-7.18 (m, 2H),
4.24 (s, 2H), 3.66 (t, 4.4 Hz, 1H), 1.80-1.65 (m, 4H), 1.58-1.47 (m, 4H).

13

C NMR

(CDCl3): δ 155.2, 142.0, 138.0, 123.7, 120.9, 70.4, 65.9, 56.9, 31.9 (2), 31.4 (2).

1-(Pyridin-2-yloxymethyl)-7-aza-bicyclo[2.2.1]heptane (154): The protected amine
148a (0.06 g, 0.02 mmol) was dissolved in a 2N KOH solution in 3:1 MeOH/H2O (10
mL) and refluxed for 48 h. When no starting material was detected by TLC, water was
added and the MeOH was removed under reduced pressure. The remaining aqueous
layer was extracted with CH2Cl2 (5 × 50 mL) and the organic layer dried with Na2SO4
and condensed to yield 154 as a yellow oil (38 mg, 95% yield).

1

H NMR (CDCl3, 400

MHz): δ 8.34 (s, 1H), 8.21 (d, J = 2.8 Hz, 1H), 7.25-7.18 (m, 2H), 4.24 (s, 2H), 3.66 (t,
4.4 Hz, 1H), 1.80-1.65 (m, 4H), 1.58-1.47 (m, 4H).

13

C NMR (CDCl3): δ 155.2, 142.0,

138.0, 123.7, 120.9, 70.4, 65.9, 56.9, 31.9 (2), 31.4 (2).

1-(6-Chloro-pyridin-3-yloxymethyl)-7-aza-bicyclo[2.2.1]heptane (155): The protected
amine (0.06 g, 0.02 mmol) was dissolved in a 2N KOH solution in 3:1 MeOH/H2O (10
mL) and heated to reflux for 48 h. When no starting material was detected by TLC,
water was added and the MeOH was removed under reduced pressure. The remaining
aqueous layer was extracted with CH2Cl2 (5 × 50 mL) and the organic layer dried with
Na2SO4 and condensed to yield 155 as a yellow solid (36 mg, 86% yield). ESI m/z =
239.3 (M+H+) 1H NMR (CDCl3, 400 MHz): δ 8.09 (s, 1H), 7.23 (s, 2H), 4.23 (s, 2H),
3.68 (t, J = 4.44 Hz, 1H), 1.81-1.75 (m, 2H), 1.70-1.64 (m, 2H), 1.57-1.50 (m, 4H). 13C
NMR (CDCl3): δ 154.7, 142.7, 137.0, 125.0, 124.5, 71.2, 66.1, 57.2, 32.1 (2), 31.6 (2).
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General procedure for preparation of oxalate salts:
Oxalic acid (1.2 eq) was dissolved in a minimal amount of diethyl ether. The oxalic acid
solution was added dropwise to a dissolved solution of the free base in diethyl ether until
a white precipitate formed. The ether was evaporated and the white solid was rinsed with
cold ether to afford the salt as an analytically pure crystalline solid.

1-(Pyridin-3-yloxymethyl)-7-aza-bicyclo[2.2.1]heptane·oxalic acid (156): Anal. Calc.
for C12H16N2O·(COOH)2·1/2H2O: C, 55.44; H, 6.63; N, 9.24. Found: C, 55.44; H, 6.03;
N, 9.06.

1-(Pyridin-2-yloxymethyl)-7-aza-bicyclo[2.2.1]heptane·oxalic acid(157): Anal. Calc.
for C12H16N2O·(COOH)2: C, 57.13; H, 6.16; N, 9.52. Found: C, 56.79; H, 6.16; N, 9.43.

1-(6-Chloro-pyridin-3-yloxymethyl)-7-aza-bicyclo[2.2.1]heptane·oxalic acid (158):
Anal. Calc. for C12H15ClN2O·(COOH)2: C, 51.15; H, 5.21; N, 8.52. Found: C, 51.10; H,
5.12; N, 8.31.
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APPENDIX
X-ray Crystallographic Data, Positional Parameters, General Displacement,
Parameter Expressions, Bond Distances, and Bond Angles
for
Phenyl-[1-(pyridin-2-yloxymethyl)-7-azabicyclo[2.2.1]hept-7-yl]methanone (148b)
and
[1-(6-Chloro-pyridin-3-yloxymethyl)-7-azabicyclo[2.2.1]hept-7-yl]phenylmethanone
(149)
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Table 1. X-Ray Crystallographic Data for 149
Empirical formula

C20H20ClN2O2

Formula weight

355.83

Temperature

150(2) K

Wavelength

0.71073 Å

Space

P2(1)/c

Volume, Z

4

Unit cell dimensions
a, Å

11.5922(15)

α, deg.

90

b, Å

13.1468(17)

β, deg.

117.549(2)

c, Å

12.3797(16)

γ, deg.

90

v, Å 3

1672.8(4)

density (calc), Mg/m3

1.413

Absorption coefficient

0.245 mm-1

F(000)

748

Crystal size

0.5 x 0.3 x 0.4 mm

θ range for data collection

2.42 to 22.50 deg.

Limiting indices

-12≤h≤12, -14≤k≤14, -13≤l≤13

Reflections collected / unique

10983 / 2190 [R(int) = 0.1216]

Completeness to theta

22.50

Refinement method

Full-matrix least-squares on F2

Data / restraints / parameters
2

100.0 %

2190 / 357 / 293

Goodness-of-fit on F

0.968

Final R indices [I>2σ(I)]

R1 = 0.0755, wR2 = 0.1861

R indices (all data)

R1 = 0.1255, wR2 = 0.2045

Largest diff. peak and hole

0.312 and -0.557 e/ Å 3
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Table 2. Atomic coordinates ( x 104) and equivalent isotropic
displacement parameters (A2 x 103) for 149
U(eq) is defined as one third of the trace of the orthogonalized
Uij tensor.
________________________________________________________________
x
y
z
U(eq)
________________________________________________________________
Cl(1)
5479(2)
1754(1)
2796(2)
50(1)
C(1)
1073(5)
6366(4) -1246(4)
26(1)
C(2)
2127(6)
6892(5) -1471(5)
31(1)
C(3)
1367(6)
7397(5) -2730(5)
35(1)
C(4)
-44(5)
7133(4) -3051(5)
29(1)
C(5)
-480(6)
7730(5) -2223(5)
34(1)
C(6)
312(6)
7195(5)
-963(5)
32(1)
N(7)
128(4)
6080(3) -2534(4)
25(1)
C(8)
-900(5)
5447(3) -2826(5)
25(1)
O(9)
-1002(3)
4912(3)
-2036(3)
31(1)
C(10)
-1760(5)
5221(3)
-4130(5)
25(1)
C(11)
-1415(5)
5404(3)
-5057(5)
30(1)
C(12)
-2242(5)
5170(3)
-6250(5)
35(1)
C(13)
-3449(5)
4738(3)
-6552(5)
35(1)
C(14)
-3819(5)
4541(3)
-5660(5)
34(1)
C(15)
-2975(5)
4780(3)
-4453(5)
31(1)
C(16)
1571(6)
5521(5)
-316(5)
28(1)
O(17)
2218(3)
4782(3)
-720(3)
34(1)
C(18)
2893(4)
4015(3)
90(5)
30(1)
C(19)
3656(4)
3384(4)
-228(5)
34(1)
C(20)
4451(4)
2681(4)
590(5)
39(2)
C(21)
4454(4)
2639(3)
1716(5)
34(1)
C(23)
2965(5)
3897(4)
1238(5)
30(1)
N(22)
3739(4)
3210(3)
2043(4)
34(1)
________________________________________________________________

133

Table 3. Bond lengths [Å] and angles [deg] for 149.
_____________________________________________________________
Cl(1)-C(21)
C(1)-N(7)
C(1)-C(16)
C(1)-C(2)
C(1)-C(6)
C(2)-C(3)
C(3)-C(4)
C(4)-N(7)
C(4)-C(5)
C(5)-C(6)
N(7)-C(8)
C(8)-O(9)
C(8)-C(10)
C(10)-C(11)
C(10)-C(15)
C(11)-C(12)
C(12)-C(13)
C(13)-C(14)
C(14)-C(15)
C(16)-O(17)
O(17)-C(18)
C(18)-C(23)
C(18)-C(19)
C(19)-C(20)
C(20)-C(21)
C(21)-N(22)
C(23)-N(22)
N(7)-C(1)-C(16)
N(7)-C(1)-C(2)
C(16)-C(1)-C(2)
N(7)-C(1)-C(6)
C(16)-C(1)-C(6)
C(2)-C(1)-C(6)
C(1)-C(2)-C(3)
C(4)-C(3)-C(2)
N(7)-C(4)-C(3)
N(7)-C(4)-C(5)
C(3)-C(4)-C(5)
C(4)-C(5)-C(6)
C(1)-C(6)-C(5)
C(8)-N(7)-C(4)

1.756(6)
1.505(6)
1.509(7)
1.538(7)
1.542(8)
1.542(8)
1.534(8)
1.500(7)
1.549(8)
1.564(8)
1.358(6)
1.254(6)
1.483(7)
1.400(7)
1.400(7)
1.374(7)
1.392(7)
1.381(7)
1.391(7)
1.452(6)
1.382(6)
1.393(7)
1.396(7)
1.366(7)
1.393(8)
1.314(7)
1.337(7)
117.3(4)
99.8(4)
114.4(5)
101.8(4)
113.8(4)
108.0(5)
104.3(4)
101.9(5)
100.5(4)
101.9(4)
110.4(5)
102.2(5)
103.0(4)
121.6(4)
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C(8)-N(7)-C(1)
123.6(4)
C(4)-N(7)-C(1)
96.3(4)
O(9)-C(8)-N(7)
121.6(5)
O(9)-C(8)-C(10)
118.5(4)
N(7)-C(8)-C(10)
118.6(5)
C(11)-C(10)-C(15)
117.9(5)
C(11)-C(10)-C(8)
123.7(5)
C(15)-C(10)-C(8)
118.4(5)
C(12)-C(11)-C(10)
121.4(5)
C(11)-C(12)-C(13)
119.6(5)
C(14)-C(13)-C(12)
120.5(5)
C(13)-C(14)-C(15)
119.5(5)
C(14)-C(15)-C(10)
121.0(5)
O(17)-C(16)-C(1)
107.8(4)
C(18)-O(17)-C(16)
116.6(4)
O(17)-C(18)-C(23)
124.7(5)
O(17)-C(18)-C(19)
116.6(5)
C(23)-C(18)-C(19)
118.4(5)
C(20)-C(19)-C(18)
119.4(5)
C(19)-C(20)-C(21)
117.3(5)
N(22)-C(21)-C(20)
125.1(5)
N(22)-C(21)-Cl(1)
116.4(4)
C(20)-C(21)-Cl(1)
118.4(4)
N(22)-C(23)-C(18)
122.6(5)
C(21)-N(22)-C(23)
117.3(5)
_____________________________________________________________
Symmetry transformations used to generate equivalent atoms:
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Table 4. Anisotropic displacement parameters (A2 x 103) for 149
The anisotropic displacement factor exponent takes the form:
-2 π2 [ h2 a*2 U11 + ... + 2 h k a* b* U12 ]
_______________________________________________________________________
U11

U22

U33

U23

U13

U12

_______________________________________________________________________
Cl(1)
C(1)
C(2)
C(3)
C(4)
C(5)
C(6)
N(7)
C(8)
O(9)
C(10)
C(11)
C(12)
C(13)
C(14)
C(15)
C(16)
O(17)
C(18)
C(19)
C(20)
C(21)
C(23)
N(22)

37(1)
27(3)
31(3)
42(3)
35(3)
39(4)
38(4)
27(2)
28(3)
31(2)
24(3)
31(3)
37(3)
36(3)
25(3)
31(3)
23(3)
33(2)
23(3)
27(3)
27(3)
28(3)
23(3)
23(3)

44(1)
30(3)
38(3)
34(3)
23(3)
32(3)
33(3)
27(2)
26(3)
33(2)
26(3)
34(3)
39(3)
38(3)
39(3)
36(3)
35(3)
45(2)
36(3)
46(3)
46(3)
36(3)
39(3)
34(3)

52(1)
19(2)
24(3)
31(3)
26(3)
31(3)
25(3)
18(2)
24(3)
29(2)
24(3)
26(3)
26(3)
21(3)
31(3)
25(3)
22(3)
24(2)
25(3)
25(3)
38(3)
32(3)
25(3)
36(3)

11(1)
-4(2)
-2(3)
0(3)
-1(2)
3(3)
-4(3)
2(2)
0(2)
2(2)
-2(2)
-5(3)
-3(3)
-2(3)
-2(3)
-3(3)
-4(2)
4(2)
2(2)
-7(3)
-3(3)
3(3)
-4(2)
1(2)

8(1)
8(1)
9(2) -4(2)
11(3) -6(3)
18(3) -8(3)
12(2) -3(2)
16(3)
0(3)
14(3)
0(3)
7(2) -3(2)
13(2)
3(2)
13(2) -3(2)
10(2)
5(2)
14(2)
0(3)
13(3) -4(3)
5(3) -1(3)
8(2) -4(3)
12(3) -5(3)
6(3)
1(3)
12(2)
7(2)
7(2)
4(2)
9(3) -2(3)
9(3)
2(3)
8(3) -3(2)
8(3)
0(3)
7(2) -4(2)

_______________________________________________________________________
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Table 5. Hydrogen coordinates ( x 104) and isotropic
displacement parameters (A2 x 103) for 149
________________________________________________________________
x
y
z
U(eq)
________________________________________________________________
H(2A)
2770(50)
6330(40) -1410(50)
41(17)
H(2B)
2710(60)
7320(50)
-760(60)
70(20)
H(3A)
1450(50)
8190(50) -2680(50)
51(17)
H(3B)
1480(60)
7070(50) -3410(60)
60(20)
H(4)
-710(50)
7280(40) -4000(50)
29(14)
H(5A)
-1490(50)
7590(40) -2520(40)
25(14)
H(5B)
-220(50)
8500(40) -2120(50)
39(15)
H(6A)
-410(60)
6950(40)
-650(50)
60(18)
H(6B)
850(50)
7650(40)
-430(40)
24(15)
H(11)
-563(19)
5709(8)
-4831(16)
30(15)
H(12)
-2003(16)
5302(7)
-6898(18)
43(17)
H(13)
-4032(17)
4574(7)
-7402(19)
70(20)
H(14)
-4663(19)
4238(8)
-5865(17)
60(20)
H(15)
-3232(16)
4643(7)
-3820(18)
25(14)
H(6A)
2240(40)
5800(30)
470(40)
15(12)
H(16B)
890(70)
5230(60)
-320(70)
90(30)
H(19)
3601(12)
3464(10) -1036(18)
26(14)
H(20)
5011(14)
2230(12)
417(16)
70(20)
H(23)
2440(20)
4320(20)
1500(40)
43(17)
________________________________________________________________
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Table 6. Crystal data and structure refinement for 148b
Empirical formula

C19H21N2O2

Formula weight

309.38

Temperature

150(2) K

Wavelength

0.71073 Å

Space group

P2(1)/c

Unit cell dimensions
a, Å

13.830(2)

α, deg.

90

b, Å

7.3959(12)

β, deg.

97.495(3)

c, Å

15.141(2)

γ, deg.

90

Volume, Z

4

Calculated density

1.338 Mg/m3

Absorption coefficient

0.087 mm-1

F(000)

660

Crystal size

0.5 x 0.4 x 0.2 mm

Θ range for data collection

3.75 to 22.49 deg.

Limiting indices

-14≤h≤14, -7≤k≤7, -16≤l≤16

Reflections collected / unique

10999 / 1987 [R(int) = 0.0487]

Completeness to Θ

22.49

Refinement method

Full-matrix least-squares on F2

Data / restraints / parameters

1987 / 0 / 289

Goodness-of-fit on F2

1.063

Final R indices [I>2σ(I)]

R1 = 0.0458, wR2 = 0.1145

R indices (all data)

R1 = 0.0498, wR2 = 0.1183

Extinction coefficient

0.0052(17)

Largest diff. peak and hole

0.268 and -0.312 e/Å3

99.5 %
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Table 7. Atomic coordinates ( x 104) and equivalent isotropic
displacement parameters (Å 2 x 103) for 148b
U(eq) is defined as one third of the trace of the orthogonalized
Uij tensor.
________________________________________________________________
x
y
z
U(eq)
________________________________________________________________
N(1)
1508(1)
1778(2)
1023(1)
22(1)
O(2)
3493(1)
-329(2)
151(1)
29(1)
N(3)
2670(1)
1858(2)
-716(1)
21(1)
O(4)
916(1)
4478(2)
1460(1)
36(1)
C(5)
2561(1)
3256(2)
-16(1)
23(1)
C(6)
3233(1)
336(2)
-588(1)
22(1)
C(7)
2795(1)
3164(2) -1447(1)
26(1)
C(8)
2441(1)
2633(2)
914(1)
23(1)
C(9)
3494(1)
-578(2) -1408(1)
21(1)
C(10)
3501(1)
4373(2)
-39(1)
28(1)
C(11)
2806(1)
-956(2) -2136(1)
24(1)
C(12)
1707(1)
4354(2)
-492(1)
27(1)
C(13)
1875(2)
4288(2)
-1479(1)
29(1)
C(14)
1404(1)
-53(2)
884(1)
25(1)
C(15)
604(1)
-945(3)
1060(1)
31(1)
C(16)
4452(1)
-1103(2)
-1422(1)
24(1)
C(17)
3670(2)
4262(3)
-1026(1)
31(1)
C(18)
787(1)
2826(2)
1338(1)
25(1)
C(19)
3075(1)
-1856(2)
-2863(1)
26(1)
C(20)
4030(1)
-2364(2)
-2883(1)
28(1)
C(21)
-53(1)
1848(2)
1518(1)
30(1)
C(22)
-139(1)
41(3)
1388(1)
32(1)
C(23)
4719(1)
-1984(2)
-2164(1)
28(1)
________________________________________________________________
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Table 8. Bond lengths [Å] and angles [deg] for 148b
_____________________________________________________________
N(1)-C(14)
N(1)-C(18)
N(1)-C(8)
O(2)-C(6)
N(3)-C(6)
N(3)-C(7)
N(3)-C(5)
O(4)-C(18)
C(5)-C(8)
C(5)-C(12)
C(5)-C(10)
C(6)-C(9)
C(7)-C(13)
C(7)-C(17)
C(9)-C(16)
C(9)-C(11)
C(10)-C(17)
C(11)-C(19)
C(12)-C(13)
C(14)-C(15)
C(15)-C(22)
C(16)-C(23)
C(18)-C(21)
C(19)-C(20)
C(20)-C(23)
C(21)-C(22)
C(14)-N(1)-C(18)
C(14)-N(1)-C(8)
C(18)-N(1)-C(8)
C(6)-N(3)-C(7)
C(6)-N(3)-C(5)
C(7)-N(3)-C(5)
N(3)-C(5)-C(8)
N(3)-C(5)-C(12)
C(8)-C(5)-C(12)
N(3)-C(5)-C(10)
C(8)-C(5)-C(10)
C(12)-C(5)-C(10)
O(2)-C(6)-N(3)
O(2)-C(6)-C(9)
N(3)-C(6)-C(9)

1.375(2)
1.395(2)
1.465(2)
1.231(2)
1.368(2)
1.496(2)
1.503(2)
1.245(2)
1.511(2)
1.533(2)
1.545(2)
1.500(2)
1.516(3)
1.525(3)
1.384(3)
1.387(2)
1.545(3)
1.379(2)
1.542(3)
1.345(3)
1.403(3)
1.389(3)
1.425(3)
1.377(3)
1.379(3)
1.353(3)
122.34(15)
118.89(14)
118.52(14)
121.18(13)
124.96(13)
96.30(12)
118.74(13)
100.04(13)
115.36(14)
100.94(13)
112.28(14)
107.77(14)
123.45(15)
119.96(14)
116.53(14)
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N(3)-C(7)-C(13)
101.51(13)
N(3)-C(7)-C(17)
101.32(14)
C(13)-C(7)-C(17)
109.72(15)
N(1)-C(8)-C(5)
116.20(14)
C(16)-C(9)-C(11)
119.37(16)
C(16)-C(9)-C(6)
118.27(15)
C(11)-C(9)-C(6)
122.33(15)
C(17)-C(10)-C(5)
103.10(14)
C(19)-C(11)-C(9)
120.17(17)
C(5)-C(12)-C(13)
103.58(14)
C(7)-C(13)-C(12)
102.64(14)
C(15)-C(14)-N(1)
121.66(17)
C(14)-C(15)-C(22)
118.35(18)
C(9)-C(16)-C(23)
119.96(17)
C(7)-C(17)-C(10)
102.83(15)
O(4)-C(18)-N(1)
120.05(15)
O(4)-C(18)-C(21)
125.13(16)
N(1)-C(18)-C(21)
114.80(15)
C(20)-C(19)-C(11)
120.58(17)
C(19)-C(20)-C(23)
119.55(17)
C(22)-C(21)-C(18)
122.19(17)
C(21)-C(22)-C(15)
120.64(18)
C(20)-C(23)-C(16)
120.35(17)
_____________________________________________________________
Symmetry transformations used to generate equivalent atoms:
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Table 9. Anisotropic displacement parameters (Å2 x 103) for 148b
The anisotropic displacement factor exponent takes the form:
-2 π2 [ h2 a*2 U11 + ... + 2 h k a* b* U12 ]
_______________________________________________________________________
U11

U22

U33

U23

U13

U12

_______________________________________________________________________
N(1)
O(2)
N(3)
O(4)
C(5)
C(6)
C(7)
C(8)
C(9)
C(10)
C(11)
C(12)
C(13)
C(14)
C(15)
C(16)
C(17)
C(18)
C(19)
C(20)
C(21)
C(22)
C(23)

27(1)
36(1)
30(1)
44(1)
30(1)
23(1)
42(1)
27(1)
29(1)
33(1)
26(1)
33(1)
41(1)
32(1)
36(1)
28(1)
40(1)
32(1)
35(1)
40(1)
28(1)
29(1)
31(1)

14(1)
26(1)
22(1)
27(1)
11(1)
23(1)
17(1)
47(1)
10(1) 28(1)
13(1) 28(1)
11(1) 27(1)
15(1) 28(1)
7(1) 26(1)
16(1)
36(1)
12(1)
33(1)
14(1)
34(1)
16(1)
30(1)
14(1)
29(1)
13(1)
43(1)
15(1)
29(1)
16(1)
39(1)
18(1)
25(1)
13(1)
28(1)
14(1)
30(1)
26(1)
37(1)
26(1)
43(1)
19(1)
36(1)

1(1)
3(1)
0(1)
-6(1)
-2(1)
1(1)
3(1)
-2(1)
3(1)
-2(1)
2(1)
0(1)
5(1)
2(1)
4(1)
2(1)
2(1)
-1(1)
0(1)
-1(1)
1(1)
6(1)
2(1)

4(1) -1(1)
1(1)
8(1)
3(1)
1(1)
10(1)
1(1)
5(1) -1(1)
1(1) -2(1)
9(1)
1(1)
2(1) -1(1)
3(1) -2(1)
4(1) -5(1)
1(1)
1(1)
5(1)
3(1)
1(1)
2(1)
4(1)
3(1)
4(1) -1(1)
0(1) -4(1)
14(1) -3(1)
3(1)
5(1)
-2(1) -3(1)
9(1)
1(1)
8(1)
5(1)
6(1) -5(1)
7(1)
2(1)

_______________________________________________________________________
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Table 10. Hydrogen coordinates ( x 104) and isotropic
displacement parameters (Å2 x 103) for 148b
________________________________________________________________
x
y
z
U(eq)
________________________________________________________________
H(7)
2893(12)
2560(20) -2012(12)
26(4)
H(8A)
2962(13)
1800(20)
1116(11)
24(4)
H(8B)
2491(12)
3720(20)
1282(12)
24(4)
H(10A)
4040(14)
3830(30)
356(13)
31(5)
H(10B)
3416(13)
5660(30)
168(12)
28(5)
H(11)
2139(15)
-590(20) -2132(12)
28(5)
H(12A)
1075(14)
3810(20)
-398(12)
28(5)
H(12B)
1715(14)
5610(30)
-241(13)
36(5)
H(13A)
1312(14)
3750(20) -1849(12)
29(5)
H(13B)
1990(13)
5530(30) -1731(13)
35(5)
H(14)
1978(14)
-600(20)
655(11) 27(5)
H(15)
560(13) -2200(30)
962(12) 35(5)
H(16)
4915(13)
-840(20) -915(13) 25(5)
H(17A)
4288(13)
3590(30) -1082(11)
28(5)
H(17B)
3693(14)
5520(30) -1309(13)
36(5)
H(19)
2584(14) -2080(20) -3364(13)
33(5)
H(20)
4222(13) -2960(30) -3374(13)
32(5)
H(21)
-552(15)
2500(30)
1734(13)
37(5)
H(22)
-713(14)
-520(20)
1523(12)
26(5)
H(23)
5435(14) -2330(30) -2185(12)
31(5)
________________________________________________________________
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